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IDENTIFICATION AND UTILITY OF DNA IN EXOSOMES 
 
Paul A. Kurywchak, B.S. 
Advisory Professor: Raghu Kalluri, M.D., Ph.D. 
 
 Cancer-associated mortality has been declining for two decades but remains a significant 
public health problem, especially when patients initially present with advanced disease. Early 
detection methods have improved survival rates but remain unavailable for a majority of cancers 
due to a lack of sensitive biomarkers or numerous limitations associated with current diagnosis 
strategies. Approaches to develop “liquid biopsies” by detecting tumor cells or DNA in the 
blood have led to several breakthroughs and create the potential for non-invasive, routine 
assessment of diseases status. However, these biomarkers are rare and currently difficult to 
isolate, especially in the early stages of disease. Exosomes on the other hand, are phospholipid 
nanovesicles that reflect the molecular contents of their cell of origin and are abundantly present 
in bodily fluids. Due to this, exosomes have attracted considerable interest as a source for 
theranostic biomarkers, and may also be important participants of tumor progression. Here, we 
characterize exosomes and their DNA content (exoDNA) from human cell lines and bodily 
fluids to assess their utility as circulating biomarkers of disease. In addition, we explore the 
origins of exoDNA, as well as its delivery and transcriptional capacity in other cells. We found 
that exoDNA from cancer cell lines and serum and urine of patients with bladder cancer is 
encapsulated within exosomes and spans the entire genome. We also discovered unique somatic 
mutations in serum and urine exosomes that are absent in tumor tissue, and propose the use of 
urine exosomes for non-invasive biomarker detection in bladder cancer. Lastly, our results 
indicate that DNA-containing exosomes may be partly comprised of vesicles that evolve from 
the nuclear membrane and horizontally transfer DNA to recipient cells. 
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Chapter 1 
Background and Significance 
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Features of pancreatic and bladder cancers and their existing theranostic limitations 
Pan-cancer statistics 
 Cancer mortality rates in the United States were at their peak in 1991 at 215.1 deaths per 
100,000 and have since fallen to 161.2 deaths per 100,000 in 2014, largely due to reductions in 
smoking rates and advances in screening and treatment strategies (Fig. 1A) (1). However, 
cancer still ranks only behind heart disease in overall causes of death, and is the leading cause of 
death in women aged 40-79 and men aged 45-79. Nearly 40% of all Americans have a lifetime 
probability of being diagnosed with invasive cancer, with an average of over 4,600 new 
diagnoses per day. In particular, men have a 20% higher incidence and 40% higher cancer-
associated mortality than woman (1). Reductions in cancer incidence often require large shifts in 
wide-scale population behavior, such as decreased smoking rates, and until other healthy 
lifestyle changes are adopted en masse, these high rates of incidence are likely to persist. It’s 
estimated that over two million cancer-related deaths have been prevented in the United States 
since the cancer mortality peak in 1991, but further improvements for detection and treatment 
are still vitally needed, especially in cancers that have seen increases in annual mortality such as 
in the pancreas or liver (Fig. 1B) (1).  
 
 
 
 
  
 
 
 
1 
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Figure 1. Cancer mortality statistics in the U.S. A) Overall cancer mortality rates by sex and 
B) in selected cancers. Reproduced with permission from (Siegel, R. L., K. D. Miller, and A. 
Jemal. 2017. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 67: 7-30.) (1). 
License number: 4304311331149. 
 
Pancreatic cancer statistics and treatment 
Advances in cancer detection and therapy as a whole have resulted in 40% or more 
fewer mortalities in the four major cancers (lung, breast, prostate, and colorectum) (1). 
However, pancreas cancer (PC) rates have not been reduced in the slightest despite 
improvements in detection and short-term survival due to therapy. 80% of PCs are classified as 
B 
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pancreatic ductal adenocarcinomas (PDAC) and are known to be the deadliest of all cancers. 
Although relatively rare (ranked 12th in incidence), PC currently accounts for the 4th most deaths 
and is expected to move to 2nd by 2030 (2). As CT scanners became more available in the 
1980s, it became possible to diagnose PC in the early stages when the disease was still localized 
and resectable by surgery (3). Even today though, less than 20% of patients are eligible for 
surgery at the time of diagnosis because 50-60% of them present with metastatic disease (Fig. 
2A) (2). This is often the case because early symptoms are rarely observed, or are unspecific  
 
 
 
 
 
 
 
 
 
Figure 2. Pancreatic cancer statistics by race. A) Stage at diagnosis and B) 5-year survival by 
stage at diagnosis. Reproduced with permission from (Siegel, R. L., K. D. Miller, and A. Jemal. 
2017. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 67: 7-30.) (1). License 
number: 4304311331149. 
 
to PC like nausea, weight loss, back pain, and irregular bowel movements when they are 
observed (2). 5-year survival is extended to 17% for the patients that receive surgery, but has 
not improved in 20 years despite advancements in therapeutic strategies, and is usually due to 
liver metastases and recurrence (3-5). Concerns have also been raised about inducing 
2 
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dissemination of tumor cells during surgery (6), but given the poor prognosis of PC in general, 
surgery is still likely to be the best path to potential cures for PC patients. 
 Gemcitabine was introduced in the late 1990s, which was reported to improve clinical 
response rates in patients with advanced PDAC to 23.8% from 4.8% when patients were given 
fluorouracil (5-FU). However, median survival was modestly extended from 4.4 months on 5-
FU to 5.7 months on gemcitabine (7), but remains a first-line therapy for all patients with 
PDAC. New targeted therapies like elotinib and chemotherapy combinations like FOLFIRINOX 
( 5-FU, Leucovorin, Oxaliplatin, and Irinotecan) and ABRAXANE (Nab-paclitaxel and 
gemcitabine) have since been established as first-line therapies, but still have only resulted in an 
overall 5-year survival increase of 5% to 8% in the last 20 years (Fig. 2B) (1-3, 8). Taken 
together, PDAC remains notoriously chemoresistant and it is obvious that much progress still 
needs to be made in the clinical management of PDAC.  
 
Pancreatic cancer risk screening  
 Due to the low incidence of PC, it would not be ideal to do population-based screening 
unless a biomarker test was highly specific, affordable, and minimally invasive. There are 
currently surveillance programs available through clinical trials for high risk patients, but are 
few in number and limited to specialized cancer centers (9). The intent is to reduce PC mortality 
through treatment of potentially precancerous lesions such as intraepithelial neoplasms, 
papillary mucinous neoplasms, diabetes, or chronic pancreatitis. However, the underlying 
biology of these pathologies and the conditions that determine if they will undergo malignant 
transformation remain somewhat unclear, and PC can also be misdiagnosed as a precancerous 
lesion. Results from a single institution, retrospective study of 1656 patients in Asia determined 
that risk of developing PC was significantly higher in older patients at the onset of chronic 
	 6	
pancreatitis and 12-fold higher risk was observed in patients with a >60 pack-year smoking 
history, so these factors may be used as baseline features for determining inclusion in a 
surveillance clinical trial for progression to PC (10). Familial PC or other hereditary syndromes 
are currently the best predictors of PC onset, with risk increasing as more family members are 
affected (9). A study of 175 consecutive patients with PDAC at Memorial Sloan Kettering 
Cancer Center estimated that 5-10% of PDAC cases are familial (11). Although some factors are 
known to increase risk of PC, the approach of how to effectively treat these early lesions is still 
not clear. Unlike high-grade dysplasia in Barrett’s esophagus or germline BRCA mutations in 
breast or ovarian cancers where preemptive surgery can dramatically reduce cancer risk, PC 
does not have clear indications that suggests performing prophylactic removal of the pancreas 
would be worth the risk (9). Therefore, in addition to identifying specific biomarkers for early 
diagnosis, PC will likely only see significant improvements in survival when combined with 
novel treatment strategies, likely involving specific targeting of known driver mutations and/or 
improvements to immune checkpoint-based methods. 
 
Biomarkers of pancreatic cancer 
 Carbohydrate antigen 19-9 (CA 19-9) is the most commonly used biomarker for PC, 
with a pooled sensitivity across multiple studies of 73% and specificity of 83% for detecting 
recurrent disease (12). Carcinoembryonic antigen is also a biomarker used in PC but has poorer 
performance than CA 19-9, with a sensitivity of 50% and a specificity of 65%, and has largely 
been replaced with CA 19-9. Both of these biomarkers are only recommended for use as 
recurrence biomarkers and not for initial diagnosis. CA 19-9 has been reported to be able to 
predict recurrence one to nine months before detection using imaging or other clinical 
indicators. However, in addition to the limited sensitivity and specificity and applicability to 
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recurrent disease only, CA 19-9 is limited due to its dependence on Lewis blood group antigens, 
which 5-10% of patients do not have (12, 13).  Numerous preclinical biomarkers have been 
developed to replace CA 19-9, but most don’t proceed past the discovery phase of development 
due to the extensive validation and associated investment required to move a candidate 
biomarker in clinical trials (13). Some serum biomarkers have reached the last phases of 
development though and shown improvement over CA 19-9 alone. For example, Capello et al. 
recently showed in three independent validation datasets that combining CA 19-9 with TIMP1 
and LRG1 in an enzyme-linked immunosorbent assay (ELISA) discriminated early-stage PDAC 
versus healthy controls with an average sensitivity of 76% and a specificity of 95% (14). In 
addition, work from Melo et al. showed that the cell surface proteoglycan glypican-1 (GPC-1) 
was specifically enriched on circulating exosomes and could distinguish patients with benign 
diseases and those with early stage PDAC with 100% sensitivity and specificity. GPC-1+ 
exosome concentrations in the blood correlated with tumor burden and was a negative predictor 
for patient survival (15). Similarly, Hu et al. also recently showed that serum exosomal GPC-1 
mRNA is also a biomarker with perfect sensitivity and specificity for PC (16). GPC-1 was 
confirmed as a biomarker for PC in multiple validation cohorts in both of these studies, and is 
currently being evaluated by other researchers to further test its validity at the mRNA and 
protein level. Biomarkers with such perfect accuracy are unprecedented in the cancer field, but 
GPC-1 could be the breakthrough that’s so desperately needed for PC, along with understanding 
the underlying genetics. Until more is known about these promising new candidates, CA 19-9 
and routine CT or PET-CT imaging will continue to be the standard approach for only 
monitoring recurrence in PC.  
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Genetics of pancreatic cancer 
 A major contributor to the emergence of cancer and its progression is genetic instability 
that leads to multistep mutation accumulation. Identifying functional mutations in master 
regulators of key cellular processes often provides insight to the disease’s aggressiveness and 
can be used for predicting patient response to therapy and outcomes. Relative to other cancers, 
the mutation rate in PDAC is low at 2.64 mutations per megabase (17, 18), with a small set of 
frequently mutated genes that have either been difficult to target therapeutically or had poor 
performance in clinical trials (Fig. 3) (19). KRAS is the primary driver gene that is mutated in 
PDAC, which has been reported to occur in 90-95% of cases (19). Furthermore, in tumors with 
wild-type KRAS, mutations in other members of the pathway are observed in 60% of cases, 
showing the central importance of this pathway in PDAC development (20).  
 
 
 
 
 
 
 
 
Figure 3. The most commonly mutated genes in PDAC. Dark color represents the minimum 
reported mutation frequency and light color represents the maximum reported mutation 
frequency across different studies. Reproduced with open access permission from (Pihlak, R., J. 
M. J. Weaver, J. W. Valle, and M. G. McNamara. 2018. Advances in Molecular Profiling and 
Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers 10: 
17.) (20).  
3 
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Due to the prevalence and importance of KRAS mutations, several attempts have been made to 
target them in human clinical trials, but have failed to improve overall survival. However, recent 
studies have shown that KRAS mutation is a prognostic indicator of poor patient outcomes (21), 
suggesting early detection of mutations in KRAS could be used to qualify candidates for 
enrollment in surveillance clinical trials. Additionally, like in a majority of cancers, TP53 is also 
commonly mutated in PDAC and thought to drive tumor development in KRAS-mutated, pre-
malignant lesions (22). TP53 is currently being targeted in clinical trials for other cancers, but 
no PDAC trials have been started yet with these therapies. SMAD4 is the third gene that has 
been reported to be mutated in >50% of cases, but the role of these mutations is still unclear. In 
addition, there are conflicting reports about the presence of SMAD4 mutations being a 
prognostic indicator (23, 24), so more research will need to be done to determine its significance 
across broader contexts such as stage, age, smoking history, etc.  
Large PDAC sequencing studies have been completed recently and were used to classify 
PDAC into subtypes based on single nucleotide polymorphism (SNP) patterns, large structural 
variants, copy number changes, and multi-platform approaches combining nucleic acid and 
protein analysis (19). The various classifications that have been generated will have to be further 
scrutinized across cohorts at multiple institutions, but may be able to discern which patients will 
respond to a given therapy and which would likely not respond or develop resistance.  
 
Bladder cancer statistics & treatment 
 Unlike pancreatic cancer, bladder cancer (BC) is common in men, ranking 4th in 
incidence among all cancers, but is not nearly as lethal as PC (77% 5-year survival for BC) 
because most patients often experience symptoms like haematuria (blood in the urine) and are 
diagnosed relatively early (1). However, 25% of patients are initially diagnosed with muscle 
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invasive BC (MIBC) or metastatic disease, and there is no effective treatment for BC metastasis 
(25). Distribution of stage at diagnosis and mortality rates for BC have not changed in over a 
decade because active population screening is not performed, but given the incidence of the 
disease, is needed greatly (Fig. 4A&B) (26). Additionally, 50-70% of patients initially  
 
 
 
 
 
 
 
 
Figure 4. Bladder cancer statistics by race. A) Stage at diagnosis and B) 5-year survival by 
stage at diagnosis. Reproduced with permission from (Siegel, R. L., K. D. Miller, and A. Jemal. 
2017. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 67: 7-30.) (1). License 
number: 4304311331149. 
 
diagnosed with non-muscle invasive BC (NMIBC) have recurrent disease and 40-50% go on to 
develop MIBC, which is treated by performing a radical cystectomy (RC) (27, 28). Meta-
analysis from Chen et al. concluded that both cancer-specific survival and overall survival is 
similar after RC in patients that present with MIBC and patients that progress to MIBC, 
indicating a need for biomarkers that define which NMIBC patients would benefit from earlier 
RC (28). The 10-year recurrence-free survival for patients that get a RC is relatively high at 
86%, but falls to 34% when the disease has spread to lymph nodes, and patients with seemingly 
localized disease can later present with recurrence in the lymph nodes. Not to mention, RC 
A B 
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significantly impacts quality-of-life, so prevention and effective therapies that don’t require 
removal of the bladder would be the best-case scenario. 
Transurethral resection of bladder tumor (TURBT) is first performed for all new BC 
cases to stage the disease, but BC arises from “field cancerization” of the entire urothelium, and 
the small specimens used for staging/diagnosis incompletely represent its molecular and cellular 
heterogeneity (29). White-light cystoscopy, a fairly invasive standard procedure is used to 
evaluate and monitor BC, yet its reliability for detection and diagnosis of early-stage BC is 
modest (30-33). Cystoscopy and cytology can be very accurate in the hands of a skilled 
urologist at a high volume academic center; however, most patients handled in smaller general 
practices are not diagnosed until the disease has progressed to MIBC. Misdiagnosis of BC leads 
to higher recurrence rates and can be lethal in the context of MIBC, due to the differences in the 
clinical management of MIBC and non-muscle invasive BC (NMIBC) (26). The high recurrence 
rates necessitate regular surveillance with cystoscopy and cytology, making BC the most 
expensive cancer on a lifetime per patient basis (26, 34, 35). Thus, more objective and sensitive 
strategies with improved prognostic capacity are urgently needed for BC monitoring. 
In the case of a NMIBC diagnosis, endoscopic resection and instillation of the bladder 
with the Bacillus Calmette-Guerin vaccine is the first line of therapy, and is reportedly more 
effective than chemotherapy (26). BCG therapy has been shown to reduce progression by 37% 
and recurrence by 40% at 1 year, and 15% at 5 years (36, 37). Unfortunately, 50% of patients 
given BCG fail to respond, dramatically reducing survival (38). As mentioned above, RC alone 
is the standard approach for treating MIBC, but 50% of these patients later die due to previously 
unobserved metastases that develop (39). If metastasis has occurred to lymph nodes or other 
sites, adjuvant chemotherapy comprised of a cisplatin combination is given after RC, which like 
PC, only results in a favorable outcome for a small minority of patients (Fig. 4B) (26). 
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Bladder cancer risk screening 
As mentioned previously, screening has reduced mortality rates for many cancers. BC 
seems favorable for screening since urine comes in direct contact with bladder tumors and is 
truly a non-invasive biomarker source. However, similarly to PC, BC is not recommended for 
population-based screening by most urological societies like the US Preventive Services Task 
Force because there are currently no suitable biomarkers for detecting early stage disease, which 
are likely the best chance to further improve BC outcomes (40, 41). Studies have been done 
using at-home dipstick tests for hemoglobin in the urine, but these suffered from pitfalls such as 
lacking appropriate control arms (41). For example, one study screened 1575 men, with 258 
testing positive and 21 later being diagnosed with BC. Long-term follow-up of these subjects 
showed only 4.8% had MIBC, compared to 23.6% in non-screened patients diagnosed 
traditionally. After 14 years of follow-up, none of the screened subjects died of BC, showing 
that this screening method was highly misleading (42).  
Also similar to PC, smoking is the top risk factor for BC development and increases risk 
2.5 times compared to nonsmokers (43). Chronic exposure to aromatic amines and other 
carcinogens has also been linked to BC, but is challenging to study and is believed to account 
for only 2-8% of new cases (44). Sequencing studies have not yet identified signatures related to 
these associated risk factors, making screening not feasible based on exposure to these 
carcinogens alone (26). More recent non-randomized trials have shown that detection of blood 
or nuclear matrix protein number 22 (NMP22) in the urine may be used as screening markers, 
but to date, thorough evaluation of screening markers in general is very limited and requires 
more comprehensive investigation.  
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Biomarkers of bladder cancer 
 Urine is an attractive liquid biopsy candidate for BC due to direct contact with the 
tumor. In addition, urine may overcome the limitations imposed by the relative paucity of tissue 
specimens and better reflect the molecular heterogeneity of BC than small biopsies. There are 
currently six FDA-approved, commercial protein/DNA-based tests for BC detection and 
surveillance, but their sensitivity and specificity for recurrent disease (35-75% and 76-94%) do 
not dramatically exceed that of cystoscopy (49-93% and 47-96%) (Table 1) (35, 45).  
 
 
 
 
 
 
 
Table 1. Pooled performance of commercially-available tests for BC surveillance. 
Reproduced with open access permission from (Clinton, T., and Y. Lotan. 2017. Review of the 
Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer. Rambam 
Maimonides Medical Journal 8: e0040.)  
 
The most promising test available, Cxbladder Monitor, hasn’t been FDA-approved but meets 
Clinical Improvement Act (CLIA) guidelines. This test combines patient data with gene 
expression signatures for 5 targets as an adjunct to cystoscopy to rule out recurrent BC and 
avoid invasive assessment methods. It can detect Ta disease with 86% sensitivity and higher 
stage disease with 95% sensitivity for recurrent disease, regardless of BCG treatment status 
(46). Further validation of this test may lead to replacing cystoscopy in particular settings (41). 
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 Lastly, recent reports assessing exfoliated cells and cell-free DNA (cfDNA) in urine 
samples of BC patients yield data supporting further research of urinary cfDNA as a biomarker 
(47-52). For instance, a retrospective next-generation sequencing/digital droplet PCR study of 
serially collected NMIBC samples revealed that high levels of tumor DNA in the urine are 
predictive of disease progression (49). The source, mechanism, and kinetics of cfDNA release in 
benign and malignant settings remain the subject of intense investigation and debate; however, 
deep sequencing efforts suggest vanishingly low frequency of tumor-associated mutations in 
cfDNA (53-56). Additionally, deep sequencing of cfDNA is an arduous task due to low 
abundance in circulation and high fragmentation (150-200 bp average length), which is even 
higher in urine (10-200 bp) due to >100-fold increase in DNase I activity (57-62). Achieving 
high global sequencing coverage of these low quality/quantity samples necessitated the 
development of new technologies, however, the prevailing clinical use of cfDNA remains 
limited (54, 56). On the other hand, growing evidence from our laboratory and others points to 
circulating exosomes as a source of genomic DNA in cancer patients, which we postulated may 
also be true for urinary exosomes, and a new biomarker class for the detection and surveillance 
of cancer (63-71).  
 
 Genetics of bladder cancer 
 Due to the “field cancerization” that occurs in BC, which is classified by detecting 
mutations in adjacent tissues that appear histologically normal, BC has been associated with 
high intra-tumor heterogeneity because multiple genetic clones are often present (29). However, 
the extent of this heterogeneity differs in NMIBC versus MIBC, with MIBC harboring more 
mutations and chromosomal rearrangements and/or amplifications/deletions (26).  
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NMIBCs typically have stable genomes, with loss of chromosome 9 being the most 
common chromosomal alteration and present in 50% of tumors. Activating mutations in TERT 
(73-83%), FGFR3 (60-70%), and PIK3CA (16-25%) are the most common oncogene alterations 
and deleterious mutations/loss in CDKN2A (15-60%), KDM6A (12-60%), and STAG2 (32-36%) 
are the most common tumor suppressor alterations in NMIBCs. Based on the prevalence of 
activation mutations in the RAS-MAPK pathway in NMIBC, it’s thought that this pathway may 
be essential for the development of >80% of these tumors (26).  
Unlike NMIBCs, MIBCs are often comprised of many subclones and contain genetic 
aberrations that are not highly observed across patients like TERT and FGFR3 in NMIBCs. For 
example, activating mutations in PIK3CA (9-20%), FGFR3 (5-20%), and HRAS (5-12%) are the 
most frequently mutated oncogenes in MIBC. Inactivating mutations in KMT2D (27%), 
ARID1A (25%), and APC (6-16%) are the most frequent mutations in tumor suppressors. Like 
most solid cancers, MIBCs frequently show loss of function or amplification of the repressors 
that regulate the tumor suppressors TP53, PTEN, and RB1. In addition, although FGFR3 
mutations are rarely observed in MIBCs, up to 40% of these tumors show upregulated 
expression of FGFR3 (26, 72). Like in PC, large-scale sequencing efforts are beginning to 
classify BC into different molecular subtypes. These classifications have shown prognostic 
importance and have also identified potentially actionable targets novel to BC. Furthermore, 
they may be useful to refer to if DNA-based biomarker tests are developed for BC. 
 
Exosomes and their DNA content 
Discovery of exosomes 
 In 1967, Peter Wolf identified that “platelet dust” containing Platelet Factor 3 (PF3 aka 
CD142) was responsible for coagulation occurring in platelet-free plasma (73), an observation 
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first reported by Chargaff and West in 1946 (74). Wolf used electron microscopy to characterize 
this platelet dust and discovered that it was rich in complex phospholipids needed for thrombin 
generation and was likely involved in blood clotting (73). This would be proved 22 years later 
when Sims et al. showed that an excessive bleeding disorder called Scott syndrome is attributed 
to a microparticle-formation defect in platelets (75). Subsequent work from Webber and 
Johnson, and Crawford, confirmed Wolf’s findings and further characterized platelet-dust as 
biologically active vesicles that are released into the circulation from platelets (76, 77). 
 Since Wolf’s discovery of platelet-dust, microparticles have been a topic of exponential 
interest and have led to debates regarding the definition of a microparticle. “Microparticles” is 
now a broad term that is synonymous with “extracellular vesicles”, and comprises the vesicle 
classes exosomes and microvesicles, which are formed through different processes. 
Microvesicles are generally described as vesicles that bud directly from the plasma membrane 
and are typically larger (100-1000nm) than exosomes (78). Exosomes however, are released 
from multivesicular bodies through the endosomal pathway and are typically 40-150nm in size 
(78, 79). Current methods for exosomes isolation often don’t distinguish exosomes from 
microvesicles of a similar size and specific markers for each population are under active 
investigation, but in this work “exosome” refers to vesicles that are < 220 nm in diameter.  
The term “exosome” was first proposed to describe 40-1000nm vesicles released by 
normal and neoplastic cell lines (80), but the association of small vesicles with multivesicular 
bodies (MVBs) and the endosomal pathway in rat reticulocytes shown by Harding et al. (81) 
caused the nomenclature to shift to a more specific subset of vesicles. Harding & Stahl made 
this discovery when they were studying transferrin receptor turnover using gold-conjugated 
transferrin, which revealed localization to small vesicles released from multivesicular 
endosomes (later called multivesicular bodies) into the extracellular space (Fig. 5) (81).  
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Figure 5. Release of exosomes containing gold-labeled transferrin. The multivesicular body 
fuses with the plasma membrane and releases the exosomes contained within. Reproduced with 
permission from (Harding, C., J. Heuser, and P. Stahl. 1983. Receptor-mediated endocytosis of 
transferrin and recycling of the transferrin receptor in rat reticulocytes. The Journal of Cell 
Biology 97: 329-339.) (81). License number: 4306541129446. 
 
Biogenesis of exosomes 
 Also studying transferrin receptor turnover on the plasma membrane (PM) of sheep 
reticulocytes, Pan et al. were the first to observe the steps of exosome biogenesis (82). First, 
inward budding of the PM results in clathrin-coated vesicles that become early endosomes. 
These endosomes undergo further inward budding that result in the creation of intraluminal 
vesicles (ILVs) containing cytosolic components. This causes the endosomal lumen to acidify 
and early endosomes mature into late endosomes and multivesicular bodies (MVBs). From here, 
the cholesterol and ceramide content of endosomal membrane at least partly determines if the 
endosomes will fuse with lysosomes, degrading its contents, or fuse with the plasma membrane, 
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releasing ILVs as exosomes (78). MVB membranes enriched with ceramide and cholesterol are 
thought to be fated for plasma membrane fusion and ILV release (83, 84).  
Exosome packaging of cytosolic molecules occurs through two separate routes, ESCRT-
dependent and ESCRT-independent mechanisms. The first requires the four endosomal sorting 
complexes required for transport (ESCRT 0, I, II, and III), which are individually comprised of 
2-7 individual proteins and associate on the membrane of endosomes. Together, these 
complexes associate with other proteins like Alix and Rab GTPases to facilitate exosome 
packaging and biogenesis. Specifically, the ESCRT-0 heterodimer complex facilitates clustering 
of ubiquitinated proteins and/or receptors on the cell surface to package them into budding 
endosomes (85). Interestingly, when ubiquitination of endosomal proteins was blocked in a 
yeast model, ILVs no longer formed in endosomes (86). The ESCRT-I heterotetramer complex 
also helps gather ubiquitinated proteins, and also passes ubiquitinated proteins from ESCRT-0 
to ESCRT-II for endosomal packaging. In addition, ESCRT-I recruits ESCRT-III to MVBs. As 
mentioned, the ESCRT-II heterotetramer is responsible for packaging ubiquitinated proteins into 
endosomes, and also associates with ESCRT-III to pinch budding ILVs off into MVBs (Fig. 6). 
Additionally, Vps4 facilitates ESCRT complex removal from membranes and recycling  (78, 87, 
88). The ESCRT-independent pathway is not as well understood, but is thought to exist because 
exosomes are still produced when all four ESCRT complexes are depleted (78). It seems to be 
dependent on sphingomyelinase and tetraspanins like CD63, which is a commonly used 
membrane protein found on exosomes. As mentioned, Rab GTPases are also involved in 
exosome biogenesis, and Rab27a and Rab27b seem to primary facilitators of MVB fusion to the 
plasma membrane. However, other Rab proteins are also involved and silencing of Rab27a or 
Rab27b still allows exosomes to be released, although in fewer numbers (89-91).  
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Figure 6. Schematic of exosome biogenesis. Endocytosis leads to the formation of early 
endosomes (EE), which become MVBs as ILVs form. MVBs can then degrade their cargo by 
fusing with lysosomes, or fuse with the plasma membrane and release ILVs as exosomes. 
Reproduced with open access permission from (Bellingham, S., B. Guo, B. Coleman, and A. 
Hill. 2012. Exosomes: Vehicles for the Transfer of Toxic Proteins Associated with 
Neurodegenerative Diseases? Frontiers in Physiology 3: 124.) (91). 
 
Exosomal cargo and protein/RNA biomarker utility 
 Exosomes carry heterogeneous cargo comprised of nucleic acids, proteins, and lipids 
that collectively reflect their cell of origin. Commonly found proteins used as markers for 
exosomes include tetraspanins (CD9, CD37, CD63, CD81, CD82), endosomal proteins 
(flotillin-1, Alix, Clathrin, Tsg101), and heat shock proteins (Hsp70, Hsp90). However, 
common exosome isolation procedures do not select for exosomes specifically, so it’s likely that 
microvesicles with a similar size/density also contain some of these protein markers (92). Other 
proteins are present in exosomes as well depending on the specific features of the cell that 
produces them. For example, exosomes from antigen-presenting cells are abundant in MHC 
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class II molecules and exosomes from immune cells in general contain proteins with immune 
function, which are absent in exosomes from non-immune cells (79). Nucleic acids (miRNA, 
lncRNA, circ,RNA, mRNA, rRNA, tRNA, ssDNA, and dsDNA) have also been found in 
exosomes, but generally seem to vary depending on their parental cell type (63, 93-97).  
Human cell-derived exosomes were first found to carry nucleic acids when Ratajczak et 
al. reported the presence of mRNA in embryonic stem cell exosomes. This study also revealed 
that the mRNA in these exosomes could be translated to protein in recipient cells (98). 
Subsequently, Valadi et al. confirmed this finding in human and mouse mast cells as well, and 
expanded on it by showing that exosomes also contain small RNAs, including microRNAs. 
They determined that many of the identified mRNA transcripts were absent in the cytoplasm of 
the exosome-producing cells, suggesting its packaging into exosomes was an orchestrated 
process and not random (99).  
 In pancreatic cancer, a number of RNA/protein biomarkers have been proposed. 
Evaluation of exosome size and concentration from the serum of healthy donors and patients 
with benign disease or PDAC has also been done, but significant differences between the three 
groups have not been observed (15, 100). As mentioned previously, the most promising 
biomarker in general for PDAC, that is also associated with circulating exosomes is glypican-1. 
GPC-1 was found to be a reliable biomarker for distinguishing patients with PDAC versus 
benign diseases of the pancreas. It was also shown that GPC-1+ exosomes contained mutated 
KRAS G12D mRNA, whereas GPC-1- exosomes from the same sample did not, suggesting that 
GPC-1+ exosomes may be primarily derived from PDAC cells driven by mutant KRAS 
expression (15). In addition, using a novel, highly-sensitive biochip, Hu et al. also found that 
GPC-1 mRNA levels in exosomes distinguished PDAC patients with the same accuracy as the 
previous study (16). Other groups have challenged the efficacy of GPC-1 as a theranostic 
biomarker for PDAC (100, 101), so additional research will likely be needed until a majority 
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consensus among the field is reached. Also using a biochip, Liang et al. found that ephrin type-
A receptor 2 (EphA2) on plasma exosomes could also identify PDAC with high accuracy from 
as little as 1 µl of plasma, and their assay outperformed ELISA (102). In addition, Costa-Silva et 
al. identified that migration inhibitory factor (MIF) in circulating exosomes may also be a 
predictor of PDAC liver metastasis (103). Lastly, studies have also shown that specific miRNAs 
in exosomes may also be PDAC biomarkers (104, 105). As with all biomarkers, these 
candidates will need to be further validated and evaluated in clinical trials, but they offer hope 
for a disease that desperately needs it. 
 Exosomes have also been explored as a source for biomarkers in bladder cancer. Unlike 
in pancreatic cancer, Liang et al. suggest that the concentration of exosomes in the urine 
distinguished BC patients from healthy controls with a sensitivity of 81.3% and specificity of 
90%, although the sample number was relatively low for each group (BC: n=16, Healthy; n=8) 
(106). Assessing the content of urine exosomes, Lin et al. identified alpha-1 antitrypsin and 
H2B1K as potential diagnostic BC protein biomarkers, but the sensitivity was poor (alpha-1 
antitrypsin: sensitivity 62%, sensitivity 97%, H2B1K: sensitivity 62%, specificity 92%), 
limiting their potential (107). In a small cohort of 8 MIBC patients and 3 healthy donors, 
Berrondo also used urine exosomes to suggest HOTAIR and four other long non-coding RNAs 
(lncRNAs) were enriched in MIBC urine exosomes, with 2-10 fold higher expression versus 
healthy donor urine exosomes by RNA sequencing and qRT-PCR (108). Lastly, Andreu et al. 
evaluated the protein and miRNA content of urine exosomes (16 NMIBC, 18 MIBC, and 9 
healthy donors) and found that miR-146a correlated with NMIBC and was a negative predicator 
for relapse, and miR-375 correlated with MIBC (109). It’s interesting to note that urine offers 
advantages over blood for BC because of proximity to the tumor, and although the exosome 
biomarker studies that have been performed thus far for BC are not as robust as what has been 
done in PC, there is great potential for urine exosomes as a biomarker.  
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 Exosomes are of particular interest in the biomarker field because they can be non-
invasively and serially collected from every bodily fluid. Furthermore, because they contain an 
array of biomolecules, there is potential for simultaneous identification of multiple biomarkers 
to increase accuracy for distinguishing between healthy versus pathogenic states and different 
stages of disease. In addition, the “mixed bag” characteristic of exosomes increases the potential 
for identifying unique biomarkers that help determine responders to therapy and overall patient 
outcomes. 
 
Functions of exosomes in cancer 
 In addition to their utility as biomarkers, exosomes have been thought to be important 
facilitators of intercellular communication through the diverse molecular cargo enclosed within 
or associated with their bi-layer, phospholipid membrane (65, 110-112). Exosomes have 
recently become a major focus in cellular crosstalk studies and have been implicated in the 
regulation of diverse physiological and pathological processes such as cellular homeostasis, 
embryonic development, angiogenesis, innate and adaptive immunity, cancer metastasis, and 
cardiovascular disease (113-120). They have also been associated with the spread of harmful 
prion proteins in neurodegenerative disorders, and as accessories to viral infection (121-123).  
 The functions of exosomes in PC development and progression have been explored and 
implicated in a wide range of processes including tumor microenvironment remodeling and 
metabolism, insulin resistance, immune modulation, and metastasis. Mu et al. demonstrated in a 
rat PDAC model that PDAC exosomes carry proteases and can degrade the ECM upon contact, 
stimulating tumor cell proliferation and metastasis (124). Additionally, Masamune et al. showed 
how PC exosomes interact with stellate cells to stimulate fibroblast activation and fibrogenesis 
to further promote tumor progression (125). Showing the systemic effects of PC exosomes, 
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Wang et al. reported that PC exosomes can interact with skeletal muscle cells and stimulate 
lipidosis and inhibit glucose intake. In addition, these exosomes could also inhibit insulin and 
PI3K/AKT signaling (126). Lastly, two groups have reported that PC exosomes can promote 
metastasis by priming the liver microenvironment. Costa-Silva et al. first showed that PC 
exosomes can be taken up by Kupffer cells and stimulate TGF-ß and fibronectin production by 
hepatic stellate cells, which then lead to recruitment of bone marrow-derived macrophages to 
create an inflammatory microenvironment (103). Yu et al. subsequently followed up on this 
work and showed that exosomes from highly metastatic cells can increase the metastatic burden 
of cells that typically have weak metastatic capacity (127). 
 Bladder cancer exosomes have also been investigated as mediators of tumor progression, 
but most of the work in this context has been done in vitro. Yang et al. suggested that BC 
exosomes inhibited cell death in a dose- and time-dependent manner through their expression of 
Bcl-2 and Cyclin D1, and upregulation of the ERK pathway in recipient cells (128). Two groups 
further expanded on this by demonstrating exosomes from MIBC cell lines and the urine of 
patients with MIBC also contain biologically active cargo capable of inducing epithelial to 
mesenchymal transition (EMT) and cell migration in primary urothelial cells (129, 130). Lastly, 
Xue et al. also observed the induction of cell proliferation, migration, and invasion through 
EMT in vitro and in vivo when exosomes carrying the lncRNA UCA1 (urothelial cancer-
associated 1) from a hypoxic MIBC cell line were delivered to cells with low expression of 
UCA1, and suggested it may also be a biomarker for BC because it could be detected in the 
serum of BC patients (131).  
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DNA in exosomes 
  Genomic DNA was first found in exosomes (exoDNA) from human and mouse 
glioblastoma cells by Balaj et al. They reported that the DNA was single stranded and c-Myc 
amplification in the cells led to increased concentrations of c-Myc RNA and DNA in matched 
exosomes. They also showed that exosomes from normal skin fibroblasts contained 
exponentially less DNA, suggesting exoDNA packaging may primarily be a feature of cancer 
cells, or at least cells with genomic amplifications (97). Subsequently, our laboratory discovered 
that exosomes from PDAC patient serum and cell lines also contained genomic DNA, but this 
DNA was primarily double-stranded and composed of large fragments >10kb in length. 
ExoDNA from these sources also spanned the entire genome and reflected the mutational status 
of the tumor, confirming that the exosomes collected from serum originated from the tumor. In 
addition, PCR products could not be amplified from the exosome-depleted serum, suggesting 
that perhaps circulating DNA is primarily enriched in vesicles and not freely floating, as 
previously believed (63). Further studies have confirmed our findings in exosomes from other 
cell types, biological fluids, and disease settings (64, 132-134). The capture of cancer-specific 
mutations in exoDNA means that circulating exosomes have utility as a non-invasive source for 
monitoring tumor genetics (63, 133).  
 
exoDNA as a biomarker 
 A major contributor to the emergence of cancer and its progression is genetic instability 
that leads to multistep mutation accumulation. Identifying functional mutations in master 
regulators of key cellular processes often provides insight to the disease’s aggressiveness and 
can be used for predicting patient response to therapy and outcomes. Multiple successive tissue 
samples are required in order to study the dynamics of these genetic events, but repeated 
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biopsies are rarely performed due to the risk of complications. Obtaining initial biopsies can 
also be very challenging or nearly impossible due to anatomical location of a tumor or health 
status of the patient (135). In addition, intratumor heterogeneity and varying ratios of malignant 
cells to normal cells in different biopsy samples can lead to inconsistent results in downstream 
analysis, compromising personalized-medicine approaches. However, exosomes are thought to 
be produced by all cells, so there is an opportunity to potentially capture more tumor mutations 
from circulating exosomes than from small samplings of solid tissue (Fig. 7).  
 
 
 
 
 
 
 
 
Figure 7. The advantage of circulating exosomes for capturing tumor mutations. As tumors 
grow, genomic instability and environmental stresses lead to the creation of new cellular clones 
with unique genotypes and expression profiles. Small biopsies samples are often not 
representative of this heterogeneity within an entire tumor, and the presence of multifocal 
primary tumors or metastases amplify the mutations that can be missed in a biopsy. Circulating 
cancer exosomes may overcome this limitation if they can be separated from healthy cell 
exosomes, or if genomic DNA is enriched primarily in cancer cell exosomes. Reproduced with 
permission from (Kalluri, R. 2016. The biology and function of exosomes in cancer. The Journal 
of Clinical Investigation 126: 1208-1215.) (65). License number: 4310990323535.  
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One study that provided initial evidence for this claim came from San Lucas et al., who 
performed whole genome, exome, and transcriptome sequencing from matched exosome and 
tissue biopsy samples from three patients with pancreaticobillary cancers. In one case, there 
were 100-fold more mutations found in exoDNA versus matched tumor tissue DNA (133). 
Although encouraging, some caution is warranted because prior studies evaluating intratumor 
heterogeneity by sequencing 10 different regions of the same tumor did not observe such a 
drastic increase in total mutational burden (136, 137). However, there are many differences 
between these studies, such as sequencing and bioinformatics approaches, and tumor types 
evaluated, so it is clear that much more research using next-generation sequencing is needed to 
fully evaluate increased capture of mutations in circulating exosomes versus tumor tissue. 
Evaluating the diagnostic potential of exoDNA versus circulating-free DNA (cfDNA), Allenson 
et al. concluded that more mutations in the driver gene KRAS could be identified in exoDNA 
versus matched cfDNA, however, 20% of healthy controls also tested positive for KRAS 
mutations, requiring further validation and careful consideration of determining allele frequency 
thresholds to limit false positive tests as much as possible (138).  
 
exoDNA in cancer 
 There is emerging new research that has given some indication of why DNA is packaged 
into exosomes and what effects this can have on recipient cells. Work from Takahashi et al. 
suggested that nuclear genomic DNA is secreted via human diploid fibroblast exosomes to 
maintain cellular homeostasis. When exosome production was inhibited, DNA accumulated in 
the cytoplasm and led to a reactive oxygen species (ROS)-dependent DNA damage response 
(DDR) mediated by the cytosolic DNA sensor, STING (stimulator of interferon genes) (68). 
However, it should be noted that inhibition of exosomal secretion may have itself caused DDR 
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activation, preceding cytosolic DNA accumulation and suggests that this phenomenon may be 
dependent on cellular stress and not necessarily a common feature of healthy cells. In addition, 
work from Kitai et al. demonstrated that treatment of breast cancer cells with the topoisomerase 
I inhibitor topotecan significantly increases exoDNA production, leading to dendritic cell 
activation through the STING pathway (69). This further suggests exoDNA accumulation is 
likely a product of DDR and potentially other stress-induced signaling events (Fig. 8).  
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Current proposed mechanism for packaging of nucleic acids into exosomes. 
Cellular stress may facilitate increased packaging on nucleic acids into intraluminal vesicles 
(ILVs) before release as exosomes. In particular, STING activation leading to ROS production 
and activation of DNA-damage response and/or nuclear breakdown during cell division may 
result in mislocalization of genomic DNA in the cytoplasm and packaging into ILVs. 
Reproduced with open access permission from (Kalluri, R., and V. S. LeBleu. 2016. Discovery 
of Double-Stranded Genomic DNA in Circulating Exosomes. Cold Spring Harbor symposia on 
quantitative biology 81: 275-280.) (139). 
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Interestingly, research from Cai et al. has demonstrated that exoDNA can be delivered to 
recipient cells, localize to the nucleus, and may be transcribed (140). Additional work from Cai 
et al. also suggests exoDNA can promote cancer-associated phenotypes in vivo, when they 
showed delivery of chronic myeloid leukemia cell line exosomes containing the BCR/ABL 
fusion gene led to the onset of weight loss, splenomegaly, and neutrophilia in rats. BCR/ABL 
mRNA and protein was found in the neutrophils of the rats, and treatment with the mRNA 
synthesis inhibitor actinomycin D prevented these symptoms (141). There is still much to be 
learned mechanistically about the function of exoDNA in recipient cells, and other work from 
Lee et al. reported that the effects of HRAS gene transfer through exosomes are transient and do 
not result in tumorigenic conversion (142). Therefore, the field is developing a better 
understanding of how exosomes interact and deliver their contents to recipient cells, but there 
remains a limited understanding of the role of exoDNA in recipient cells and whether its 
function is context-specific (Fig. 9). 
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Figure 9. Routes of exogenous dsDNA delivery to other cells. Free dsDNA enters cells 
through 1) micropinocytosis and 2) endocytosis in a sequence-dependent manner (143-145). 
exoDNA can enter cells through 1) micropinocytosis, 2) endocytosis (multiple mechanisms), 3) 
phagocytosis, and 4) membrane fusion (146). Reproduced with permission from (Kurywchak, 
P., and R. Kalluri. 2017. An evolving function of DNA-containing exosomes in chemotherapy-
induced immune response. Cell research 27: 722.) (147). License number: 4297870031325 
 
Bakhoum et al. recently published that errors in chromosomal segregation lead to 
cytosolic DNA accumulation and subsequent STING activation, promoting tumor cell invasion 
and metastasis (148). The rate of metastasis formation decreased when chromosomal instability 
was suppressed, and metastatic nodules were found to have a significantly higher degree of 
chromosomal instability when compared to the primary tumor. Chromosomal instability was 
associated with high rates of micronuclei formation, which were structurally unstable and led to 
leakage of genomic DNA in the cytoplasm. In addition to STING activation, cytosolic DNA 
resulted in non-canonical NF-κB activation and increased nuclear localization of the 
transcription factor RelB (148). Although this study was not directly linked to exoDNA 
production, it supports previous work and suggests exoDNA is at least a consequence of 
chromosomal instability, if not an active contributor to a metastatic phenotype. Further research 
is needed to fully elucidate the mechanisms of exoDNA packaging and whether the production 
of cytosolic DNA and exoDNA has a specific function, or are merely consequences of cellular 
crisis. Regardless, there appears to be immediate utility for exoDNA and more broadly 
exosomes for non-invasive monitoring of cancer, and potentially other pathological conditions 
as well. 
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Dissertation goals and major findings 
In this work, we aimed to further address intra- and extraluminal DNA localization in 
exosomes as well as its potential intra- and extracellular origins. Whole genome sequencing of 
DNase I-treated cell line exosomes collected using two different exosomes isolation methods 
confirmed that exoDNA spans the entire genome and accurately reflects the copy number 
profile of the exosome-producing cells. Furthermore, we used digital PCR to evaluate the 
clinical utility of exoDNA for identifying prominent driving mutations (KRASG12D and 
TP53R273H) in 48 serum samples from PDAC patients, 7 from intraductal papillary mucinous 
neoplasm (IPMN) patients, 9 chronic pancreatitis (CP) patients, and 114 healthy donors. This 
confirmed that exoDNA could be used to identify PC driving mutations and also revealed that 
these mutations can also be detected in a small number of seemingly healthy donors (66). 
Follow up of these healthy donors was not possible, but would be needed in further studies to 
determine if these mutations predicted development of PC.  
Expanding the potential of exoDNA in BC, we evaluated the DNA content of DNase I-
treated urinary exosomes from healthy donors and BC patients to determine the utility of 
exoDNA for identifying BC mutations. We found that urine samples from BC patients 
contained significantly more exosomes and more exoDNA. Whole exome sequencing of urinary 
exoDNA, matched serum exoDNA, tumor DNA, and peripheral blood mononuclear cell 
(PBMC) DNA (normal control) from five BC patients and subsequent comparative variant 
analysis revealed superior capture of somatic mutations, many distinctive driver gene variants, 
and a subset of miRNA-binding domain mutations in urinary exoDNA compared to serum 
exoDNA and tumor tissue DNA. Taken together, our results demonstrate the potential 
theranostic value of urinary exoDNA analysis for BC and offer a starting point to further refine 
such techniques and analyses to generate robust, rigorous, and reproducible assays for BC 
management.  
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In addition, due to the unknowns that remain in regard to how genomic DNA is 
packaged into exosomes, we investigated an alternative possibility that vesicle production 
occurs directly from the cell nuclei. We compare these nuclear vesicles (NVs) to exosomes and 
explore horizontal exoDNA transfer and expression in recipient cells. We demonstrate that 
isolated nuclei can generate small vesicles, which are similar to exosomes in size, encapsulated 
by a bi-layer membrane, and also contain significant amounts of nuclease-protected, 
intraluminal DNA. Thus, it is likely that a fraction of the DNA-containing exosomes may derive 
from nuclear vesicles (NVs), which are possibly taken up and/or fuse with endosomes or 
multivesicular bodies in the cytoplasm during exosome biogenesis. Finally, we show that 
exoDNA can be traced to recipient tissues and is transcribed within recipient cells. Taken 
together, this work provides further evidence that evaluation of exoDNA as a biomarker should 
be pursued heavily in future research efforts and also suggests that exoDNA may be shuttled 
directly from NVs.  
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Materials and methods for experiments with PDAC cell line and serum/plasma samples 
Cell culture 
The following human cell lines were used: Panc-1 (American Type Culture Collection 
(ATCC)), T3M4 (Cell Bank, RIKEN BioResource centre), HPNE (ATCC), HMLE (ATCC), BJ 
fibroblasts (ATCC), MDA-MB-231 (ATCC), DOV13 (ATCC). The following murine cell lines 
were used: 4T1 (ATCC), 1493 (primary pancreas fibroblast cell line generated in our 
laboratory). All cell lines were regularly tested for mycoplasma contamination. Panc-1 and 
T3M4 cells were cultured in RMPI-1640 supplemented with 10% (v/v) FBS, 100 U ml-1 
penicillin and 100 µg ml-1 streptomycin. HPNE cells were cultured in 70% (v/v) DMEM 
(glucose-free, 2 mM L-glutamine, 1.5 g L-1 sodium bicarbonate) supplemented with 25% (v/v) 
Medium M3 Base, 5% (v/v) FBS, 10 ng ml-1 human recombinant EGF, 5.5 mM D-glucose (1 g 
L-1), 750 ng ml-1 puromycin, 100 U ml-1 penicillin, and 100 µg ml-1 streptomycin). HMLE cells 
were cultured in DMEM/F12 media supplemented with 5% (v/v) horse serum, 20 ng ml-1 EGF, 
0.5 mg ml-1 hydrocortisone, 100 ng ml-1 cholera toxin, 10 µg ml-1 insulin, 100 U ml-1 penicillin, 
and 100 µg ml-1 streptomycin. BJ fibroblasts, MDA-MB-231, 4T1, and 1493 cells were cultured 
in DMEM supplemented with 10% (v/v) FBS, 100 U ml-1 penicillin and 100 µg ml-1 
streptomycin. All cell lines were incubated in a humidified atmosphere at 37°C with 5% CO2 
and 20% O2. 
 
Exosome isolation 
Exosomes were collected from the conditioned media (CM) as described previously 
(Fig. 10) (149). Briefly, 5 million cells were grown in 225 cm2 flasks overnight, washed with 
PBS, and then incubated in serum-free media for 48 hours. Serum samples from healthy donors 
or PDAC patients were thawed at 37°C prior to exosomes extraction. Next, the CM or serum  
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Figure 10. Schematic of exosome and exoDNA isolation from cell culture supernatants. 
 
was sequentially centrifuged at 800g for 5 minutes and then at 2,000g for 10 minutes to remove 
cellular debris and large vesicles. The cleared supernatant was passed through a 0.2 µm pore 
filter and ultracentrifuged (UC) at 100,000g for 2 hours at 4°C. For isolation using PEG-based 
Total Exosome Isolation Reagent (Thermo), CM was centrifuged and filtered as above, then 0.5 
volume of the reagent was added and incubated for 1 hour at 4°C. Samples were centrifuged at 
10,000g for 1 hour at 4°C. For both methods, the supernatant was discarded and exosomes were 
resuspended in 200 µl PBS for downstream processing. For nanoparticle tracking analysis 
(NanoSight LM10), 10 µl aliquots of exosome suspension were diluted 1:100 in cell culture-
grade H2O and 30 second videos were captured in triplicate to determine size and concentration.  
For immunoblotting, exosomes were resuspended in 100 µl Triton X-100 lysis buffer (see 
below). 
10 
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Sucrose gradient ultracentrifugation  
Exosomes were resuspended in 2 ml of HEPES/sucrose stock solution (2.5 M sucrose, 
20 mM HEPES/NaOH, pH 7.4), placed in a SW40 tube (Beckman), and overlaid with 9 ml 
linear sucrose gradient (2.0-0.25 M sucrose). For DiO/DNA extraction experiments, exosomes 
were resuspended in 1 ml of HEPES/Sucrose stock solution (0.25 M sucrose, 20 mM 
HEPES/NaOH, pH 7.4) and layered on top of a 10 ml linear sucrose gradient. Gradients were 
subjected to UC for 16 hours at 100,000g at 4°C. Gradient fractions of 1 ml were collected from 
top to bottom and density of each fraction was measured with a refractometer. Fractions were 
diluted and washed in PBS by UC for 2 hours at 210,000g at 4°C. Pellets were resuspended in 
Triton X-100 lysis buffer for western blot or in PBS for nanotracking analysis and DNA 
extraction. 
 
Western blot 
After UC, exosomes were resuspended in Triton X-100 lysis buffer (150 mM NaCl, 1% 
(v/v) Triton X-100, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4, 50 mM 6-aminohexanoic acid, 
10 mM EDTA supplemented with protease inhibitors [Complete EDTA-free, Roche] added just 
before use) and were allowed to lyse in the same tubes for at least 1 hour on ice. Protein loading 
was normalized based on BCA protein quantification and samples were denatured at 95°C for 5 
minutes in 1X Laemmli loading dye ([5x] 10% [w/v] SDS, 10 mM b-mercapto-ethanol, 20% 
[v/v] glycerol, 0.2 M Tris-HCl pH 6.8, 0.05 % [w/v] bromophenolblue). Exosome lysates were 
loaded onto 10% (v/v) polyacrylamide gels and separated at 50 mA for 1 hour using the X-Blot 
system (Thermo). Proteins were transferred to PVDF membranes (Immobilon P) by wet transfer 
for 2 hours at 80V. Membranes were blocked for 30 minutes in 5% BSA in TBST at room 
temperature and then incubated overnight at 4°C with primary antibodies at 1:500 dilution: anti-
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Flotillin-1 (sc-25506, Santa Cruz Biotech), anti-CD9 (ab92726, Abcam). Blots were washed 3 
times in TBS-T (10 minutes each) and incubated with 1:500 anti-Rabbit (A0545, Sigma) 
horseradish peroxidase (HRP)-conjugated secondary antibody for 1 hour at room temperature. 
Blots were washed 3 more times with TBST and then developed using chemiluminescence 
reagents (Pierce).  
 
Transmission electron microscopy (TEM) 
Fixed specimens were placed onto 400 µm mess carbon/formvar-coated grids and 
allowed to absorb for at least 1 minute. Grids were rinsed with PBS and placed in 2.5% 
glutaraldehyde in 0.1 M phosphate buffer for 15 minutes, rinsed in PBS and distilled water, 
allowed to dry, and stained for contrast with uranyl acetate. The samples were viewed with a 
Tecnai Bio Twin TEM (FEI) and images were taken with an AMT CCD camera (Advanced 
Microscopy Techniques). 
 
DNase I treatment and DNA extraction 
Isolated exosomes were treated with 25 U ml-1 DNase I in 1X DNase I buffer and 
incubated for 30 minutes at 37°C. DNase I was then inhibited by incubation with 2mM EGTA 
(final concentration, pH 8.0) for 10 minutes at 65°C. DNA from cell culture exosomes was 
extracted using the DNeasy Blood and Tissue kit (Qiagen), according to the manufacturer’s 
instructions and eluted in 50 µl H2O. DNA from serum exosomes was extracted using the 
QIAamp DNA Micro kit (Qiagen) according to the manufacturer‘s instructions with the 
following modifications: exosomes lysis was performed at 56°C for 1 hour, and DNA was 
eluted with 25 µl of elution buffer. Concentration was measured using the Qubit 3.0 high 
sensitivity dsDNA kit. Assays to test Qubit reliability and DNase I performance under different 
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conditions are provided in Fig. 11A-C. Fragment size distribution was assessed using the High 
Sensitivity DNA Kit (Cat#5067-4626) on the Agilent Bioanalyzer 2100 according to the 
manufacturer’s instructions. The standard curve used for Bioanalyzer measurements is shown in 
Fig. 11D. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Quality control experiments to test DNase I and Qubit 3.0 performance. 
Readings were performed in biological triplicates. A) Panc-1 DNA was serially diluted 1:2 four 
consecutive times to determine measurement accuracy. Concentration readings were nearly 
identical using broad- range sensitivity reagents (r2 = 0.996) and high-sensitivity reagents (r2 = 
0.986). B) DNase I performance was tested in either PBS or C) H2O using DNase I from two 
different suppliers, with and without reaction buffer. DNA concentration was measured using 
high sensitivity Qubit 3.0 reagents. D) Standard curve for Bioanalyzer measurements. Seconds 
on the x-axis correspond with fragment length in base pairs on the y-axis. 
cyTOF of exosome-bound beads 
11 
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Panc-1 and T3M4 cells were plated in two 225 cm2 flasks each containing 50 µM 5-
Iodo-2’ –deoxyuridine (IdU, Cat# I7125, Sigma), incubated overnight, and CM collected as 
above after switching to serum-free media for 24 hours. Exosomes were collected by UC and 
resuspended in 250 µl PBS. Exosomes were fixed by adding an equal volume of 3.2% PFA in 
PBS for 10 minutes at room temperature, washed by UC, and resuspended in 100 µl PBS. Fixed 
exosomes were permeabilized by adding 2 volumes of cold 100% methanol and incubating at -
20°C for 20 minutes. The samples were washed once more by UC in PBS supplemented with 
0.1% BSA for 2 hours and exosomes were resuspended in 45 µl 0.1% BSA in PBS. Final 
exosome preparations were incubated with anti-GAPDH-Er170 antibody (final concentration 
0.02 mg ml-1 Cat# A00178, GenScript) and incubated with gentle rocking overnight at 4°C. 
Exosomes were washed by UC as above, resuspended in 200 µl PBS, and incubated with 5 µl 
Aldehyde/sulfate latex beads for at least 1 hour before cyTOF analysis. 
 
DiO labeling of exosomes 
Serum-free CM were collected, cleared of debris by sequential centrifugation as 
described above, and passed through a 0.2 µm pore filter. 5 µl Vybrant DiO (Invitrogen) was 
added to the cleared media (5 µl x 25 ml-1 CM) and incubated for 45 min at 37°C. Exosomes 
were then collected by UC for 2 hours, pellets resuspended in 1 ml HEPES stock solution, and 
layered onto a sucrose gradient. DiO in stock, serum-free RPMI-1640 was processed in the 
same way as CM and used as a negative control. 
 
DNA library preparation and WGS 
Libraries were prepared from purified DNA samples using the SureSelect QXT Whole 
Genome Library Prep kit, following the manufacturer’s instructions (Agilent, Version D0). 
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Sample
Total Reads 
(million)
Mapping Rate 
(%)
Duplicate Rate 
Mapped Reads (%)
Mean Target 
Coverage
Median 
Target 
Coverage
8X
(%Targets)
6X
(%Targets)
4X
(%Targets)
Panc-1 Cells 274.46 94.04 6.28 6.26 5.71 19.99 45.56 76.8
Panc-1 Nuclei 617.93 94.38 7.58 14.35 13.37 87.12 93.48 96.32
Panc-1 Conditioned Media 419.45 94.35 6.99 9.02 8.23 52.64 73.5 87.6
Panc-1 exoDNA +DNase (UC) 160.48 93.96 6.92 3.61 3.14 2.06 8.79 32.94
Panc-1 exoDNA (UC) 583.38 94.41 7.32 12.53 11.64 75.68 84.49 90.57
Panc-1 exoDNA +DNase (Isolation 
Reagent) 412.48 94.74 6.94 9.44 8.74 57.63 75.98 87.83
Panc-1 exoDNA (Isolation 
Reagent) 314 94.83 6.48 7.52 6.91 36.37 61.84 83.41
T3M4 Cells 505.83 94.39 7.53 11.19 10.18 71.83 85.99 93.7
T3M4 Nuclei 188.14 95.29 5.21 4.69 4.2 7.58 21.97 54.25
T3M4 Conditioned Media 212.29 94.62 6.55 5.3 4.74 13.49 31.94 62.39
T3M4 exoDNA +DNase (UC) 99.91 92.98 6.5 2.75 2.21 1.45 5.21 18.73
T3M4 exoDNA (UC) 383.77 94.36 6.81 9.62 8.76 57.67 75.74 87.72
T3M4 exoDNA +DNase (Isolation 
Reagent) 138.26 94.3 6.56 3.78 3.24 4.62 13.65 36.61
T3M4 exoDNA Isolation Reagent 164.15 94.31 6.82 4.3 3.79 6.85 19.18 46.43
4T1 Cells 535.86 94.34 12.8 13.49 12.58 85.2 93.01 96.45
4T1 exoDNA UC 535.09 95.58 8.82 19.34 16.78 79.32 86.34 92.35
DOV13 Cells 528.94 95.57 6.6 12.08 11.73 83.32 91.63 95.73
DOV13 exoDNA +DNase UC 184.8 90.11 9.97 3.17 2.67 1.15 5.92 25.03
DOV13 exoDNA UC 530.86 94.26 7.26 11.38 11.2 75.56 85.37 92.24
Prepared libraries for Panc-1, T3M4, 4T1, and DOV13 samples were submitted for 76 bp 
paired-end WGS on an Illumina HiSeq 2000. The median coverage for these samples was 8.2X 
(Table 2). Separately, resequencing for Panc-1 (only Panc-1 cell DNA and Panc-1 exoDNA 
+DNase I) and first-time sequencing for MDA-MB-231 samples was performed using the same 
library preparation method as above and 151 bp paired-end WGS on an Illumina NextSeq 500. 
Median coverage for these samples was 11.5X.  
 
 
 
 
 
 
 
 
 
Table 2. Total reads and coverage of cell line WGS samples. 
 
Alignment and variant analysis 
Sequencing reads were aligned to the hg19 reference genome using BWA-MEM (150). 
Aligned reads were further processed using the GATK tool kits for duplicate removal, base 
recalibration, and variant calling (151). The called variants were annotated using ANNOVAR 
based on UCSC known genes (152). Variants listed in dbSNP129, 1000 genome, and EPS 6500 
were filtered out to remove potential germline variants. Protein function impact assessment of 
variants were performed using SIFT and Polyphane scores (152). 
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Copy number analysis 
Copy number profiles from sequencing data were obtained by first deriving segments 
using Circular Binary Segmentation (CBS) (153) and then deriving log2 ratio scores with an in-
house tool, exomeCN, which is a modified version of HMMcopy (154) tuned for our data. 
Gene-level copy number assessment was derived from copy number segments using the R 
package CNTools (155). The log2 scores > 0.5 were considered copy number gains while log2 
scores < -0.5 were considered copy number losses. The correlation of copy number profiles 
between cell and paired exosomes samples were calculated using Pearson and Spearman 
correlation. A compilation of known cancer genes: CancerGenes (156), Network of Cancer 
Genes (157), and the Sanger Cancer Gene Census in COSMIC (158) was used for cancer gene 
annotation. 
 
Healthy individual and PDAC patient serum samples (66) 
Serum samples were collected from 171 patients who underwent surgery major 
pancreatic resection due to underlying diagnosis at the Department of General, Visceral and 
Thoracic surgery, University Medical Center of Hamburg, Germany between 2003 and 2013. 
The diagnosis was confirmed upon histopathological analyses of the resected material. The 
study was approved by the Ethics Committee of the Chamber of Physicians in Hamburg, 
Germany (PVN1045). Written consent for using the samples for research purposes was obtained 
from all patients prior to surgery or blood drawing. Blood samples of patients with suspected 
PDAC were obtained from central venous catheter from each patient directly before surgery. 
After collection of the blood samples, serum was separated from the blood by centrifugation at 
3400×g for 10 minutes and these serum samples were kept frozen at –80°C. Samples were 
chosen randomly from the pre-existing tumor bank unaware of the underlying disease at the 
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time of exosome analysis. Histopathological proven diagnoses (PDAC, IPMN, chronic 
pancreatitis and in a few cases autoimmune pancreatitis, common bile duct cancer, pancreatic 
cystadenoma, pancreatic neuroendocrine tumor, duodenal adenoma, and uterine sarcoma) was 
revealed after digital PCR analyses of serum-derived exosomal DNA. None of the patients with 
malignant disease received preoperative cancer related therapies. 
 Blood samples of healthy individuals were collected by MD Anderson Blood Bank. 
Serum samples were collected in Vacutainer Plus plastic serum tube (Becton Dickinson, 
Franklin Lakes, NJ) and stored at room temperature until the end of the day. Samples were then 
spun at 3000xg for 20 minutes and then stored at 4°C overnight. The serum was then extracted 
the next day and the samples were stored at -80°C.  
 
Digital PCR (66) 
We aimed to detail the experimental procedures following the guidelines proposed for 
reporting digital PCR data (159) and proceeded with analyses of our results keeping in mind 
considerations reported on sensitivity and specificity (160). To identify KRASG12D and TP53R273H 
mutations in human sample exosomal DNA, digital PCR was performed using Taqman SNP 
Genotyping assays on the Quantstudio 3D system (Thermo Fisher) according to manufacturer‘s 
instructions. The probe assay ID used are AH6R5PI (KRAS G12D c35G>A (WT:C —> 
MUT:T) and AHWSLEX (TP53 R273H c.818G>A (WT: C —> MUT:T). For human samples, 
6.5µl of DNA was added regardless of DNA concentration. Samples with DNA concentration 
greater than 8ng/µl were diluted 1:3 in elution buffer to ensure proper cluster separation during 
analysis. The functional abundance was calculated as below, and reported as a percentage using 
the formula below: 
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Functional Abundance (%) = Total number of mutant alleles / Total number of alleles 
(mutant and wildtype) – average false positive rate. 
 
The analysis of the digital PCR data was performed with the manufacturer’s software 
(QuantStudio 3D Analysis Suite). The detection limit of the assay was determined using 
exosomal DNA extracted from cell lines. Exosomal DNA extracted from HMLE cell lines were 
used as wild- type DNA, while that extracted from Panc-1 was used as mutant DNA for KRAS 
(heterozygous G12D) and TP53 (homozygous R273H). False positive rate and threshold 
(intensity) limit for mutant alleles were determined using wild-type DNA at concentrations 
representative of that of samples (four replicates at 0.1, 0.2 and 0.3ng/µl for patients (totaling 
0.65, 1.3, 1.95ng of DNA), and 1 and 2ng/µl for healthy donors (totaling 6.5 and 13ng of DNA). 
The average false positive rate was calculated from all replicates, and used to calculate the 
reported functional abundance. A titration of mutant exosomal DNA from 10% to 0.01% with a 
total of 0.5, 1, and 3ng DNA was performed, determining the functional abundance threshold at 
0.25%. We also conducted a no template control (n = 1) and did not detect any mutant or wild-
type alleles. 
 
Nuclei isolation & NV collection 
Cells were harvested with 0.05% trypsin, centrifuged for 3 minutes at 2000 rpm, 
resuspended in 5 ml PBS, and then centrifugation was repeated. The supernatant was discarded 
and cell pellets were resuspended in three volumes of ice-cold NP-40 lysis buffer (10 mM Tris-
HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.5% v/v NP-40 supplemented with protease 
inhibitors [Complete EDTA-free, Roche] added just before use) and isolated as described 
previously (161). Briefly, cells were aspirated in and out of a 1000 µl pipette 10 times, 
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incubated on a rotating wheel at 4°C for 10 minutes, and nuclei were pelleted by centrifugation 
(200g, 5 minutes, 4°C). The supernatant (cytosolic fraction) was removed with a pipette and 
then nuclei were resuspended in lysis buffer and centrifuged two more times to remove any 
remaining cytosolic components. Final nuclei pellets were resuspended in 1 ml serum-free 
RPMI-1640 media and counted using a Cellometer Mini (Nexcelom). Five million nuclei were 
placed in 25 ml isotonic buffer (serum-free RPMI-1640 media or PBS were used with the same 
results) in a 225 cm2 flask and placed in a humidified incubator (37°C, 5% CO2, 20% O2). 
Nuclear vesicles (NVs) were collected at indicated time points following the protocol used for 
exosome isolation. 
 
PKH26 labeling of exosomes 
Exosomes were isolated as described above, resuspended in 1 ml PKH dye solution (4 µl 
PKH26 in 996 µl Diluent C [10 mM Tris-HCl, 0.1 mM EDTA, 1 mM DTT, 0.15% Triton X-
100, 200 µg ml-1 BSA, 50% glycerol, pH 7.4]) and incubated for 5 minutes at room temperature. 
Two volumes of RPMI-1640 supplemented with 1% BSA was added to each sample and 
incubated for 5 minutes at room temperature. Volume was adjusted to a total of 11 ml prior to 
UC. The supernatant was discarded, exosomes were resuspended in 1 ml RPMI-1640 and then 
UC was repeated twice to wash away excess PKH26 dye. Exosomes were resuspended in 210 µl 
PBS and used for further analysis.  
 
Fluorescence microscopy 
For fluorescence microscopy, nuclei were incubated in NP-40 lysis buffer with 10 µg ml-
1 4,6-Diamidino-2-phenylindole DAPI, (10 min at room temperature), and washed twice with 
lysis buffer as described above. Nuclei were resuspended in 1ml serum-free RPMI-1640 
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containing 1 µM ER-Tracker Red dye (Invitrogen), incubated 30 min at 37°C, washed twice 
with RPMI-1640, and plated on round glass coverslips in a 12-well plate for 1 hour. The 
medium was aspirated and the settled nuclei were fixed to the coverslips by adding 4% 
paraformaldehyde (PFA, 2 min at 37°C). Coverslips were then mounted on glass slides and 
images were obtained with a Zeiss Observer 2.1 microscope (Zeiss Zen software, 2012 Blue 
edition).  
 For DNA tracking, Hoechst 33342 was added to the cell medium to a final 10 µg/ml and 
incubated for 30 minutes at 37°C. The cells were then plated onto glass coverslips in 6-well 
plates (1x105 cells/well). After overnight incubation, cells were washed with PBS and incubated 
with SYTO16-labeled genomic or exoDNA (5 ng in 500 µl serum-free media) for 3 hours. Cells 
were washed two times with PBS, incubated for additional 24 hours in serum-free media and 
fixed by adding 4% PFA to a final 1% for 10 minutes at room temperature. The cells were 
washed twice with PBS, and permeabilized with 0.1% (v/v) Triton X-100 in PBS for 5 min. 
After 2 more washes the cells were incubated for 20 minutes at room temperature in Phalloidin 
647 solution (Invitrogen, 5 µl Phalloidin in PBS supplemented with 1% BSA). The cells were 
rinsed two more times and the coverslips were mounted on glass slides and allowed to dry at 
4°C overnight. In a parallel experiment, exosomes were collected and subjected to fluorescent 
measurement to detect exoDNA. Five million Hoechst 33342-labeled or unlabeled cells per 
experimental condition were plated in 225 cm2 flasks and incubated as above; 250 ng of 
SYTO16-labeled gDNA or exoDNA added was to the media, incubated for 3 hours, the media 
removed, cells washed twice in PBS, and incubated for another 24 hours in serum-free media. 
Exosomes were then collected by ultracentrifugation, resuspended in 100 µl PBS and treated 
with DNase I. Exosome concentration was assessed by NanoSightTM, and then fluorescence was 
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measured at an of 355 nm excitation to detect Hoechst 33342 signal (genomic DNA) and at 488 
nm to detect SYTO16 signal (exogenous DNA).   
For exosome tracking in cell culture, 5 x 104 cells were plated on glass coverslips in 12-
well plates and allowed to adhere overnight. Then the cells were washed with PBS and placed in 
500 µl serum-free media. PKH-labeled exosomes were added (1x109) to the cells and incubated 
for 3 hours. cells were fixed and permeabilized as above, washed with PBS and stained with 
Phalloidin 488 solution (Invitrogen) (1% BSA in PBS, 5 µl Phalloidin 488) for 20 minutes at 
room temperature. After another PBS wash, coverslips were mounted on glass slides. 
 
PCR & Sanger sequencing 
One million 1493 cells were plated in 75 cm2 flasks, allowed to adhere overnight, and 
treated with 1x1010 DNase I-treated Panc-1 or T3M4 exosomes for 3 hours. The cells were 
immediately collected for DNA extraction, or washed and incubated for another 24 hours with 
fresh serum-free media before DNA isolation. In another experiment, the cells were treated for 3 
hours with 1 µg Panc-1 or T3M4 exoDNA (either naked or packaged with lipofectamine 2000). 
After cell collection and DNA extraction, human TP53 exon 5-8 were PCR amplified as 
described previously (63), generating a 1564 bp product (forward 5’-
TTCCTCTTCCTACAGTACTCC-3’, reverse 5’-CCTGCTTGCTTACCTCGCT-3’ ) under the 
following cycling conditions: 94°C for 1 minute, 2 cycles of 94°C for 10 seconds, 67°C for 30 
seconds, 70°C for 30 seconds, 2 cycles of 94°C for 10 seconds, 64°C for 30 seconds, 70°C for 
30 seconds; 2 cycles of 94°C for 10 seconds, 61°C for 30 seconds, and 70°C for 30 seconds; 35 
cycles of 94 °C for 10 seconds, 59 °C for 30 seconds, 70 °C for 30 seconds. Additionally, for 
PCR with animal tissue DNA, human KRAS exon 2 was PCR amplified, generating a 166 bp 
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product (forward 5’-AAGGCCTGCTGAAAATGACTG-3’, reverse 5’-
AGAATGGTCCTGCACCAGTAA-3’) under the same cycling conditions used above. 
PCR products were purified using the QIAquick PCR purification kit (Qiagen), and 
Sanger sequencing was performed using BigDye terminator kit (v3.1, Life Technologies) 
according to the manufacturer’s instructions, with primers for TP53 Exon 5-8 (forward 5’-
TCTTCCTACAGTACTCCCCT-3’, reverse 5’-GCTTGCTTACCTCGCTTAGT-3’). 
Sequencing products were separated on an ABI 3730 automated sequencer (Life Technologies).  
 
RT-qPCR 
One million 1493 cells were plated in 75 cm2 flasks, allowed to adhere overnight, and 
treated with 1x1010 DNase I-treated Panc-1 or T3M4 exosomes for 3 hours. The cells were 
immediately collected for RNA extraction, or washed and incubated for another 24 hours with 
fresh serum-free media before RNA isolation using the RNeasy Isolation Kit (Qiagen). cDNA 
was synthesized according to the manufacturer’s instructions (High-Capacity cDNA Reverse 
Transcription Kit, Cat# 4368813, Life Technologies) and used for RT-qPCR (SuperScript III 
Platinum One-Step qRT-PCR Kit with ROX, Cat# 11745-500, Thermo) in a QuantStudio 7 Flex 
Real-Time PCR system, using primers for human wild-type KRAS (forward 5’- 
ACTTGTGGTAGTTGGAGCTGG-3’, reverse 5’-TTGGATCATATTCGTCCACAA-3’) and 
primers for mouse ß-actin (forward 5’- CATGTACGTTGCTATCCAGGC-3’, reverse 5’- 
CTCCTTAATGTCACGCACGAT-3’) as an internal control under the following cycling 
conditions: 50°C for 3 minutes, 95°C for 5 minutes, followed by 40 cycles of 95°C for 15 
seconds and 60°C for 30 seconds. Fold-change was calculated using the DDCt method and 
statistical significance was determined using Welch’s t-test (unpaired, two-tailed, * £0.05, ** 
£0.005). 
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Experimental animals 
Swiss Nude mice were purchased from the Experimental Radiation Oncology Breeding 
Core at MD Anderson and maintained and handled at the MD Anderson Cancer Center 
vivarium following the guidelines outlined by the National Institutes of Health and MD 
Anderson Animal Care and Use Committee (Protocol #12-13-11831). 
 
Exosome tracking in vivo 
Panc-1 exosomes were collected and labeled with PKH26 as described above. Labeled 
exosomes collected from the 48 hour-conditioned media from two 225 cm2 flasks were injected 
intraperitoneally (IP) into nude mice and the animals were sacrificed 3 hours later. Livers and 
pancreata were dissected and frozen in OCT compound (Tissue-Tec) for confocal 
epifluorescence microscopy or flash frozen for DNA extraction (DNeasy Blood and Tissue Kit). 
Tissue sections were stained with DAPI before analysis to visualize cell nuclei. PCR was carried 
out with the primers for exon 5 of human KRAS: (forward, 5’-
AAGGCCTGCTGAAAATGACTG-3’, reverse, 5’-AGAATGGTCCTGCACCAGTAA-3’) and 
cycling conditions as described above.   
 
Statistical analysis 
Statistical analysis was performed using Prism 7 (GraphPad) and data are expressed as 
mean ± SD. Statistical significance was determined using Welch’s t-test (unpaired, two-tailed, * 
£ 0.05, ** £ 0.005). Exosome and exoDNA measurement experiments were done in biological 
duplicate or triplicate.  
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Materials and methods for experiments with BC samples 
Patient information and specimen collection 
All samples were preserved in the Bladder SPORE Tissue bank (University of Texas 
MD Anderson Cancer Center) and the collection and analysis was approved by the Institutional 
Review Board (Protocol PA15-0970). All patients provided informed consent and all samples 
were properly de-identified. Three patients with NMIBC, one Ta low-grade (P3), two T1 high 
grade (P1 and 2) and three patients with MIBC (P4-6) were initially entered into the study. Two 
NMIBC patients (P1 and 2) had progressed to MIBC at the time of sample collection enrolled in 
the study, prior to neo-adjuvant therapy. Blood and urine were collected prior to transurethral 
biopsy, except from two blood samples (P2 and P5) that were collected 32 and 15 days after the 
biopsy was performed. One patient (P1) received neo-adjuvant intravesical Bacillus Calmette-
Guerin (BCG) therapy others were given 3-5 cycles of various chemotherapy regimens. For 
each biopsy, H&E staining and staging was performed by a blinded Bladder Core pathologist. 
Human urines were purchased from Bioreclamation IVT (Baltimore, MD) and sera from healthy 
volunteers were from the University of Texas MD Anderson Cancer Center Blood Bank. 
 
Isolation of exosomes from urine and serum  
Urine samples (35 ml for healthy volunteers, 4 ml for BC patients) were centrifuged and 
supernatants placed on ice. Tamms-Horsfall glycoprotein pellets were dissolved in DTT (200 
mg ml-1) to liberate exosomes and centrifuged, the supernatants combined and remaining pellets 
were discarded. Supernatants were passed through 0.20 µm syringe filters (Corning, 431219) to 
remove large vesicles and debris prior to ultracentrifugation (UC) (200,000 x g, 3 hours).  
Resultant pellets were resuspended in PBS and a second UC wash step performed. Final 
exosome pellets were resuspended in 210 µl PBS and a 10 µl aliquot used for nanoparticle 
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analysis. Remaining exosomes were incubated with DNase I (25 U/ml, Promega, 9PIM610, 
Madison, WI) for 30 min at 37oC and the reaction was terminated by incubation with 1X DNase 
I stop solution (Promega) for 5 min at 65oC (Fig. 12). Exosomes from serum samples were 
collected as previously described (149). Briefly, patient sera (1 ml) were thawed on ice, adjusted 
to 11 ml with PBS, and passed through a 0.22 µm syringe filters. Exosomes were collected by 
UC and DNase I treated using the same procedure described for urine exosomes above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Schematic of the exosome isolation procedure for human urine samples. 
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Nanoparticle tracking analysis  
10 µl exosome suspensions were diluted 1:100 in cell culture grade H2O and loaded via 
syringe pump onto a NanoSightTM (LM10, Malvern Instruments, United Kingdom). Tracking 
was performed at 25oC with the camera level set at 13-16 for urine samples and 12-13 for serum 
samples to perform readings at a similar brightness for each sample. Three 30 second videos per 
sample were used to determine the size range and concentration of the particles. 
 
Immunogold labeling and transmission electron microscopy (TEM) 
Serum and urine exosomes were subjected to a total of three UC (210,000 x g) washes in 
PBS, 2 x 3 hrs and then 1 x 14 hrs. Exosomes were resuspended in 50 µl PBS with 2.5% EM-
grade glutaraldehyde. Immunogold labeling with anti-CD9 primary antibody (Table 3) and 
TEM were performed as described previously (149). 
 
 
 
 
 
 
Table 3. Antibodies used for BC experiments. 
 
Western blot analysis  
Exosome pellets from 35 ml urine and 1 ml serum from healthy donors were lysed for 1 
hour on ice in 100 µl urea buffer (8M urea, 2.5% SDS, 5 µg ml-1 leupeptin, 1µg ml-1 pepstatin, 
1mM phenylmethylsulphonyl fluoride, PMSF). Lysates were cleared by centrifugation (22,000 
x g, 4oC, 15 minutes) and protein concentrations determined using a modified BCA assay. Each 
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sample was measured in duplicate using BSA standards in the urea lysis buffer. Lysates were 
denatured in 1X Laemmli loading buffer at 95oC (5 min) and 40 µg per lane were run on 4-12% 
Tris-Bis gel using 1X MES running buffer (Invitrogen, NP0002, Carlsbad, CA) at 150V for 1 
hour and transferred to PVDF membrane (Millipore, IPVH00010, Burlington, MA) by wet 
transfer at 32V for 2 hrs. Membranes were blocked for 1 hour (room temperature) with 5% non-
fat dry milk in TBS-T (1X TBS, 0.05% Tween-20) and incubated overnight with primary 
antibodies at 4oC in 2% milk in TBS-T (Table 3). Membranes were washed 4 x 15 min with 
TBS-T and incubated with 2o antibodies for 1 hour at room temperature in 2% milk in TBS-T 
(Table 3). For band visualization, membranes were washed 4 x 15 minutes with TBS-T and 
incubated with ECL western blotting substrate per manufacturer’s instructions.  
 
DNA extraction 
DNA from urine exosomes (35 ml urine for healthy donors, 4 ml for BC patients), serum 
exosomes (1 ml serum for both healthy donors and BC patients), PBMCs and tumor tissue (1 
mg). DNA from PBMCs and tumor tissue was extracted using the DNeasy Blood and Tissue kit 
(Qiagen, 69506, Hilden, Germany) and with QIAamp MiniElute columns (Qiagen, 57414, 
Hilden, Germany) for exosomes samples, according to the manufacturer’s instructions. DNA 
concentration was measured using the Qubit 3.0 high sensitivity dsDNA kit (Thermo, Q32854, 
Waltham, MA) and fragment sizes assessed using the Bioanalyzer 2100 High Sensitivity DNA 
Kit (Agilent, 5067-4626, Santa Clara, CA). Samples were stored at -20oC. 
 
Targeted PCR and Sanger sequencing 
 DNA from urinary exosomes, tumor tissue, and PBMCs was PCR-amplified in 25 µl 
volume (for primers see Table 4) using KAPA2G Robust Hot start DNA Polymerase (KAPA 
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Biosystems, KK5522, Basel, Switzerland) following manufacturer’s instructions in a T100 
Thermocycler (Bio-Rad, Hercules, CA). PCR products were separated on 1% agarose gel for 1 
hour at 100V and purified using the Wizard SV Gel and PCR Clean-Up System (Promega, 
TB308, Madison, WI). Sanger sequencing was performed using the same primer sets, at the 
Sequencing and Microarray Facility (MD Anderson Cancer Center). The resulting sequences 
were aligned and probed for somatic variants with DNA STAR SeqMan Pro software (Version 
12.3.1). 
 
 
 
 
 
 
Table 4. Primer sets used for PCR and Sanger sequencing. 
 
DNA library preparation and whole exome sequencing 
Prior to library preparation, sera and urinary exoDNA were subjected to whole-genome 
amplification (WGA) using the REPLI-g Mini Kit (Qiagen, 150025, Hilden, Germany). Library 
preparation and whole exome sequencing was performed at the Sequencing & Microarray 
Facility (University of Texas MD Anderson Cancer Center). A total of 23 DNA samples 
(PBMC reference unavailable for P3) 12-15 µg per sample were submitted for sequencing. 
DNA capture/ library preparation was performed using the SureSelect Clinical Exome Kit V2 
(Agilent, 5190-9501, Santa Clara, CA) followed by sequencing on an Illumina HiSeq 3000. 
Coverage and other sequencing quality metrics are provided in Table 5.  
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Table 5. Whole exome sequencing total reads and coverage data. Red numbers are below 
the quality threshold: Mapping rate (³95%), Duplicate mapped reads (£25%), Mean coverage 
(³100X), Median coverage (³50X) 
 
Quality control, sequence alignment, and variant calling 
Estimates of concordance and contamination for matched sample - normal (PBMC) pairs 
were performed using Conpair (162) for detection of sample swaps and cross-patient 
contamination in WES experiments (Table 6A-E).  
 
 
 
Table 6A. Total somatic variants in each patient sample.  
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Table 6B. Concordance, Tumor (T) vs. PBMCs (Normal, N) 
 
 
 
 
Table 6C. Concordance, Urine (U) vs. PBMCs (Normal, N) 
 
 
 
 
Table 6D. Concordance, Serum (S) vs. PBMCs (Normal, N) 
 
 
 
 
Table 6E. Contamination, Tumor (T), Urine (U), and Serum (S) vs. PBMCs (Normal, N)  
 
Identification of somatic mutations using WES data from PBMC DNA, tumor tissue DNA, and 
urine and serum exoDNA was performed according to the Standards and Guidelines for the 
Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus 
Recommendation of the Association for Molecular Pathology, American Society of Clinical 
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Oncology, and College of American Pathologists as described by Li et al., and Chang et al. 
(163, 164). Globus Genomics (165), a Galaxy-based platform that uses Amazon Web Services 
for scalable compute and storage resources was used for the reference genome alignment and 
GATK-based variant calling. Variant annotation was performed using ANNOVAR (166). 
Identified variations were annotated with additional information from the UniProt database 
(167, 168) and Cancer Gene Index. Somatic driver mutations with strong or potential clinical 
significance were designated if the somatic mutation was identified in a gene that was (a) 
annotated as an oncogene or tumor suppressor gene by UniProt keywords; (b) associated with 
bladder carcinogenesis (Cancer Gene Index); or (c) has an entry in the COSMIC database. An 
overview of this bioinformatics approach is also presented as a flowchart in Fig. 13. 
 
 
 
 
 
 
 
 
Figure 13. Bioinformatics workflow for interpreting whole exome sequencing data. 
 
Enrichment and comparative analysis 
Analysis of somatic mutations with strong or potential clinical significance in BC patient 
NGS data was performed as follows. All genes containing somatic mutations were annotated 
using information from the Lynx Knowledge Base (LynxKB) (169). Enrichment analysis to 
13 
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discover over-represented functional categories and molecular pathways in the identified gene 
sets was done using Lynx enrichment analysis tools and ToppGene (169, 170). Construction of 
molecular networks and pathways harboring somatic variations of strong clinical and diagnostic 
significance was also performed using the Lynx suite of tools (169). STRING 10 was used as an 
underlying global network for network-based gene prioritization (171). The identification of 
miRNAs potentially interacting with mutated UTRs was done using the information from 
SomaMIR 2.0 database and ToppGene (170, 172). 
Comparative analysis of somatic mutations in individual patients was performed using 
customized analytical pipelines specifically developed in-house for this purpose. The somatic 
mutations identified in samples from the same patient were compared to establish which 
variations are unique to a particular sample and which are shared among two or more. 
Comparative analysis of somatic mutations between individual patients was performed using the 
additional customized analytical pipelines developed in-house. The results of analyses were 
visualized in part using InteractiVenn (173). 
 
Statistical analysis 
Data are expressed as mean ± SD, with the exception of Fig. 15C, which is expressed as 
mode ± SD. Statistical analysis was performed using GraphPad Prism version 7. Non-
parametric unpaired, two-tailed Mann-Whitney tests were performed independently for all urine 
and serum datasets, but were represented as single graphs in Fig. 15B-C & E-F. The Holm-
Sidak method was used to determine statistical significance, **P£0.05. 
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Chapter 3 
Characterization of exosomes and exoDNA 
	
	
	
	
	
	
	
	
	
	
	
This chapter is partly based upon (Yang, S., S. P. Che, P. Kurywchak, J. L. Tavormina, L. B. 
Gansmo, P. Correa de Sampaio, M. Tachezy, M. Bockhorn, F. Gebauer, A. R. Haltom, S. A. 
Melo, V. S. LeBleu, and R. Kalluri. 2017. Detection of mutant KRAS and TP53 DNA in 
circulating exosomes from healthy individuals and patients with pancreatic cancer. Cancer 
biology & therapy 18: 158-165.). “Taylor & Francis is pleased to offer reuses of its content for 
a thesis or dissertation free of charge.” 
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Characterization of PDAC cell line exosomes and exoDNA 
PDAC cell line exosomes share common features  
Exosome production from two pancreas cancer cell lines (Panc-1 and T3M4) was 
measured by NanoSightTM. We observed an accumulation of exosomes maintained for 72 hours 
after serum withdrawal from sub-confluent cultures (Fig. 14A). Exosome concentration was not 
impacted by DNase I treatment (Fig. 14B) and nanotracking analysis	also showed that exosomes 
had a nearly uniform exosome diameter, with a major peak at approximately 150nm for both 
cell lines (Fig. 14C). Both Panc-1 and T3M4 exosomes were positive for EV markers flotillin-1 
and CD9 by western blot (Fig. 14D&F), as well as the tetraspanin markers CD9, CD63, and 
CD81 by flow cytometry analysis (Fig. 14E). Ultracentrifugation using a bottom-loaded sucrose 
gradient yielded homogeneously distributed fractions positive for the EV marker flotillin-1 (Fig. 
14F), thus confirming uniform size distribution.  Transmission electron microscopy (TEM) 
showed spherical structures in the 40-150nm diameter range with lipid bilayer membranes 
(Fig.14G).  
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Figure 14. Characterization of PDAC cell line exosomes. A) Exosomes were collected from 
conditioned media at the indicated time periods and particle concentrations were measured by 
NanoSightTM. B) Exosome quantification was performed after exosomes were in the presence or 
absence of DNase I and the DNase I inhibitor EGTA. C) Representative NanoSightTM plots for 
Panc-1 (left) and T3M4 exosomes (right). D) Western blots of exosomal lysates probed for 
Flotillin-1 (Flot-1) and CD9. E) Flow cytometry analysis of Panc-1 (top) and T3M4 (bottom) 
exosomes for common tetraspanin exosome markers.  F) Contents of Panc-1 and T3M4 
conditioned media ultracentifugation pellets were separated by density using a sucrose gradient. 
Aliquots from 1 ml fractions were subjected to Western blotting and probed for the exosomal 
marker Flot-1. G) Transmission electron microscopy (TEM) of Panc-1 and T3M4 exosomes. 
	 60	
Large fragments of dsDNA are predominately enclosed within exosomes 
To address intra- or extra-luminal localization of exoDNA, DNA was extracted from 
Panc-1 and T3M4 exosomes that were treated with DNase I at distinct steps relative to exosome 
lysis and with or without the ion chelating agent EGTA to inhibit DNase I activity. Quantitative 
measurements following DNA extraction showed that when DNase I was applied before 
exosome lysis, 65-75% of the total exosomal DNA in the untreated control group was 
recovered. In contrast, only 10% DNA was recovered when DNase I treatment was performed 
following exosome lysis (Fig. 15A&B). When exosomes were exposed to DNase I prior to 
lysis, in the absence of DNase I inhibitor EGTA, roughly 40% of the DNA remained intact, 
suggesting that intraluminal DNA became susceptible to DNase I digestion when exosomal 
membranes were lysed. This observation further supports the concept of exosomal membranes 
serving as protective barriers for intraluminal exoDNA. When exoDNA content was normalized 
to exosome numbers, T3M4 exosomes contained more DNA (base pairs/particle) than Panc-1 
exosomes; however, this difference was lost after DNase I exposure (Fig. 15C).  
To further characterize the DNA cargo in PDAC exosomes, Panc-1 and T3M4 cells were 
incubated with the thymidine analog 5-iodo -2’ -deoxyuridine (IdU), which is incorporated into 
DNA during S phase of the cell cycle. Exosomes were isolated, permeabilized, and incubated 
with Er170 conjugated anti-GAPDH antibody (internal control). After subsequent binding to 
aldehyde sulfate latex beads, exosomes were analyzed using cytometry time of flight (CyTOF). 
Panc-1 exosomes showed the following distribution: 8.9% beads double-positive for both IdU 
and GAPDH, 10.6%, positive for GAPDH alone and 5.9% for IdU alone. For T3M4 exosomes, 
27.3% of exosome-bound beads were double-positive for IdU and GAPDH, 26.7% for GAPDH 
only, and 4.2% for IdU only (Fig. 15D). These results suggest that in the exosomes population 
under consideration, a heterogeneous distribution of DNA-containing and GAPDH-positive 
populations is detected, with a fraction of exosomes that do not contain IdU labeled DNA. The 
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higher percentages of IdU-positive beads in T3M4 exosomes is consistent with the observed 
higher DNA content per particle (Fig. 15C). In addition, this concept of heterogeneity within 
exosome population was also observed by traditional flow cytometry when these cell line 
exosomes were probed for tetraspanins, showing non-uniform expression (Fig. 14E). 
 Fragment length assessment of exoDNA from untreated or DNase I-treated exosomes 
showed large (up to 10 kb detection limit) fragments in both conditions. In contrast, very little 
exoDNA remained when DNase I treatment was performed after exosome lysis (Fig. 15E).  
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Figure 15. PDAC cell line exosomes contain large intraluminal DNA fragments. A) Total 
Panc-1 and T3M4 exoDNA content was measured by Qubit. DNase I and EGTA (DNase I 
inhibitor) were added before (B) or after (A) exosome lysis. B) In the same experiment, percent 
DNA remaining after treatment was calculated and compared between conditions. C) In the 
same experiment, DNA content was normalized to exosome concentration (base pairs particle-1). 
D) Cellular DNA was labeled with IdU, exosomes isolated, permeabilized, incubated with anti-
GAPDH antibodies, bound to Aldehyde/sulfate latex beads, and analyzed by CyTOF. E) 
Exosomes were isolated, treated with DNase I and EGTA at indicated time points (B, before 
lysis; A, after exosome lysis), and exoDNA isolated and analyzed by capillary electrophoresis 
(Bioanalyzer Station). F) DiO-labeled exosomes from Panc-1 and HPNE cells, and control 
RPMI medium were layered on top-to-bottom sucrose gradient, separated by ultracentrifugation, 
1 ml fractions collected, and exosome-containing fraction visualized using spectrophotometry at 
488 nm wavelength. The density of exosome-containing and adjacent fractions was determined 
by refractometry. Subsequent DNA extraction confirmed the presence of exoDNA in the 
gradient layer with the highest fluorescence intensity (total DNA amount is shown). 
 
Lastly, we evaluated the exoDNA in sucrose-fractionated exosome preparations. 
Ultracentrifugation of DiO-labeled exosomes from Panc-1 and HPNE (normal human epithelial-
like pancreas ductal cells) layered on top of a sucrose gradient showed a distinctly visible, single 
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Panc-1 ExosHPNE ExosRPMI Control
band (Fig. 16). A negative control (exosome-free RPMI medium) confirmed the specific 
labeling of exosome membranes with DiO dye (Fig. 16). The density of the DiO-positive and 
adjacent 1 ml gradient fractions was in the range typically associated with exosomes (1.11-1.20 
g/ml). To assess DNA concentration, fluorescence intensity at 488nm excitation was measured 
in all gradient layers. Only one fraction at 1.15 g/ml (DiO-positive band) from the Panc-1 cell 
line generated an RFU measurement above the background (Fig. 15F). The presence of DNA in 
this fraction was confirmed after subsequent DNA extraction.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Visualization of DiO-stained exosomes in sucrose gradient preparations. 
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Whole genome sequencing reveals that exoDNA is reflective of cell DNA 
DNA was isolated from human pancreas (Panc-1, T3M4), ovarian (DOV13), mammary 
(MDA-231), and murine mammary (4T1) cancer cell line cells and exosomes (as well as Panc-1 
and TM4 nuclei, conditioned media, and PEG reagent-isolated exosomes (Fig. 17A-E). 
Libraries for WGS were prepared and run on an Illumina HiSeq 2500, resulting in a mean 
coverage of 8.6X across all samples (Table 2). Copy number and variant analysis demonstrated 
that DNA from both untreated and DNase I-treated exosomes (pre-lysis) closely corresponded 
to the DNA isolated from matched cells (Fig. 17A&B, Tables 1-6). These observations further 
support the claim that cells generate large populations of exosomes, which collectively contain 
genomic DNA that spans all chromosomes and is not enriched for specific loci.  
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Figure 17.  Copy number analysis reveals that exoDNA spans all chromosomes. ExoDNA 
from A) Panc-1, B) T3M4, C) MDA-MB-231, D) 4T1, and E) DOV13 cell lines was subjected 
to whole genome sequencing followed by copy and variant number analyses. Vertical shaded 
regions represent different chromosomes. DNase I treatment before exosome lysis was applied 
where indicated to confirm sequencing of only intraluminal DNA. Black indicates the raw 
profile and red represents the segmented (average) copy number profile on a log2 scale. The 
profiles show chromosomal gains (above the baseline) and losses (below the baseline).  
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Characterization of healthy donor and PDAC patient serum exosomes and exoDNA (66) 
Serum exosomes from healthy donors (n = 114) and patients (PDAC, IPMN, CP, or 
others) (n = 76) were enriched using size exclusion filtration and ultracentrifugation and particle 
size and concentration was assessed using nanoparticle tracking analysis (NanoSightTM). This 
revealed that exosome preparations from both populations were mostly similar in size, as shown 
in a representative NanoSightTM plot for healthy and PDAC patient serum exosomes (Fig. 18). 
 
 
 
 
 
 
 
 
 
 
Figure 18. Representative concentration and size distribution of exosomes from healthy 
donors (top) and PDAC patients (bottom). 
 
 Despite the low volume of some serum samples (as low as 150 µl), sufficient amounts of 
exoDNA were collected for downstream digital PCR (dPCR) experiments, with a circulating 
exosomal DNA concentration range of 0.102 – 1.35 ng/ml for patients (0.11 – 1.22 ng/µl for 
PDAC patients, 0.106–0.584 ng/µl for IPMN, 0.13– 1.35 ng/µl for CP, and 0.102–0.476 ng/µl 
for others), and 0.212 – 19.7 ng/µl for healthy subjects (Fig. 19). 
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Figure 19. Healthy donor (left) and patient (right) serum exoDNA concentrations. 
 
Characterization of urine and serum exosomes from healthy donors and BC patients 
Urine exosomes have some distinct features from serum exosomes  
Nanotracking analysis revealed that in healthy donors, urinary exosomes are smaller than 
serum exosomes (mode diameter of 130.3 ± 24.6 nm vs. 177.4 ± 28.2 nm) and more exosomes 
were present in the sera compared to an equal volume of urine (1.6x1011 ± 2.8x1010 mL-1 vs. 
3.6x109 ± 1.9x109 mL-1, respectively, (Fig. 20A-C). Western blot analysis identified typical 
exosomal proteins in the exosomal lysates, including CD9, CD81, and flotillin-1 (FLOT-1) in the 
urinary (U) exosomes and CD9, CD63 and FLOT-1 in the serum (S) exosomes (Fig. 20D). TEM 
of exosomal preparations showed similar vesicular structures in the serum and urine (Fig. 20E). 
Immunogold TEM also confirmed CD9 presence on both urinary and serum exosomes (Fig. 20E). 
Together, this analysis revealed that although serum and urine exosomes share some markers 
typically found on all exosomes, they also had some unique characteristics, suggesting different 
tissues may have distinct exosome biogenesis and packaging mechanisms. 
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BC patient urine samples contained elevated exosome and exoDNA concentrations 
Nanotracking analysis showed significantly higher exosome concentrations in the urine 
of BC patients (Fig. 20B). No significant difference in exosome size was observed (Fig. 20C). 
Quantitative assessment showed higher urinary exoDNA content in the BC patients compared to 
healthy donors when normalized per sample volume or per exosome (Fig. 20F&G).  
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Figure 20. Characterization of exosomes from the urine and serum of healthy donors and 
BC patients. A) Representative graphs for nanoparticle tracking analyses of exosomes from the 
urine and serum of a healthy donor. B) Total exosomes as determined by nanoparticle analysis, 
normalized to input volume (particles x ml-1). C) Exosomes mode diameter as determined by 
nanoparticle analysis. D) Western blot analysis of exosome lysates from healthy human urine 
and serum probed for exosome markers CD9, CD63, CD81, and FLOT-1. E) TEM and CD9 
immunogold staining of the urinary and serum exosomes from healthy volunteers. Scale bars = 
100nm. F, G) exoDNA measurements in the urine and serum normalized per mL biological 
fluid F) or per particle G). Data are expressed as mean ± SD, with the exception of panel C, 
which is expressed as mode ± SD. Non-parametric Mann-Whitney (unpaired, two-tailed) tests 
were performed independently for all urine and serum datasets, but were represented as single 
graphs in panels B, C, E, & F. The Holm-Sidak method was used to determine statistical 
significance, **P£0.005. Healthy donors; BC;  P1,   P2,  P3,  P4,  P5,  P6. 
 
Urine and serum exosomes contain large fragments of genomic DNA 
Capillary electrophoresis (BioanalyzerTM) was used to compare exoDNA fragment 
quality (average length) before and after healthy urine exosomes were treated with DNase I 
(Fig. 21A), as well as to compare fragment quality in the exosomal and tumor tissue DNA 
preparations (Fig. 21B-D). The quality was similar, suggesting that the majority of the DNA 
fragments are localized within the exosomal lumen and are shielded from enzymatic 
degradation (Fig. 21A). As expected, tumor tissue yielded high-quality DNA, with fragments 
ranging between 1,521 - 12,216 bp (Fig. 21B). Both urine and serum exoDNA presented with a 
similar DNA profile, with urinary exoDNA fragments ranging from 1,593 - 16,295 bp and 
serum exoDNA ranging from 1,508 - 29,640 bp (Fig. 21C-D).  
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Figure 21. Comparative analysis of DNA from exosomes and matched tumor tissues. A) 
DNA from healthy donor urine exosomes from a healthy volunteer which were untreated (left) 
or pre-treated with DNase I (right). B) DNA from tumor biopsies and C) DNase I-treated serum 
and D) urinary exosomes from BC patients and analyzed by capillary electrophoresis.  
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Chapter 4 
Utility of exoDNA as a cancer biomarker 
	
	
	
	
	
	
	
	
	
 
 
This chapter is partly based upon (Yang, S., S. P. Che, P. Kurywchak, J. L. Tavormina, L. B. 
Gansmo, P. Correa de Sampaio, M. Tachezy, M. Bockhorn, F. Gebauer, A. R. Haltom, S. A. 
Melo, V. S. LeBleu, and R. Kalluri. 2017. Detection of mutant KRAS and TP53 DNA in 
circulating exosomes from healthy individuals and patients with pancreatic cancer. Cancer 
biology & therapy 18: 158-165.). “Taylor & Francis is pleased to offer reuses of its content for 
a thesis or dissertation free of charge.” 
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Detection of PDAC-associated DNA mutations in human serum exosomes (66) 
Establishing thresholds for mutation detection by digital PCR (dPCR)  
 We previously reported the detection of a heterozygous KRAS mutation at codon 12 
(KRASG12D c35G>A) and a homozygous TP53 mutation at codon 273 (TP53R273H c.818G>A) 
using the genomic DNA from PDAC cell line, Panc-1, derived exosomes (63). To determine the 
detection limit of KRASG12D and TP53R273H mutations in exosomes by digital PCR, we used 
exosomal DNA derived from Panc-1 cells as well as HMLE cells (wild-type for KRAS at codon 
12 and wild-type for TP53 at codon 273). Exosomal DNA from HMLE cells (n = 3 replicates) 
indicated a 0 ± 0% rate of detection for KRASG12D mutation and 0 ± 0.05% rate of detection for 
TP53R273H mutation, validating their wild-type status at both loci. In contrast, exosomal DNA 
from Panc-1 cells (n = 3 replicates) indicated a 59.62 ± 0.89% rate of detection for KRASG12D 
mutation and 99.67 ± 0.13% rate of detection for TP53R273H mutation, validating their reported 
genotype for each mutation. Known amounts of HMLE exosomal DNA were used to determine 
the false positive detection rates upon digital PCR analyses for KRASG12D and TP53R273H 
mutations. A stringent threshold of 8800 A. U. (arbitrary units, referring to the intensity of 
mutant allele for each mutation was used, reflecting an average false positive rate of 0.040% and 
0.034% for KRASG12D and TP53R273H mutation, respectively (Fig. 22A). Importantly, the wild-
type HMLE exosomal DNA concentration range in these experiments reflects the range of 
exosomal DNA concentration obtained from serum samples of patients (vide infra). Whether 
relatively low or high concentrations of exosomal DNA were used, the average false positive 
rate remained consistent (Fig. 22A), supporting the reliability of the chosen limit set for 
defining false positives (< 8800 A. U.). To define the sensitivity of detection of KRASG12D and 
TP53R273H mutations, we next performed a titration experiment, in which different amounts of 
Panc-1 mutant exosomal DNA were mixed with different amounts of wild-type HMLE 
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exosomal DNA. These mixtures reflected the ‘spiked- in’ mutation at an expected frequency of 
0.05, 0.1, 0.25, 0.5, 1.0, 5.0 and 10% (Fig. 22B). The titration experiment revealed that the 
sensitivity of detection for both mutations by digital PCR was 0.25% (Fig. 22B), below which 
mutant alleles could not be detected reliably, especially at low concentrations (0.5 ng in Fig. 
22B).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Definition of digital PCR parameters using cell line-derived exoDNA. A) 
Determination of the average false positive rate using HMLE exoDNA. B) Determination of the 
sensitivity threshold by measuring the relative functional abundance of Panc-1 exoDNA spiked 
in HMLE exoDNA. Defined percentages of spiked Panc-1 exoDNA with HMLE exoDNA were 
expressed as an expected percentage of spiked mutation. The sensitivity threshold was set to 
0.25% to reliably detect either KRASG12D (left) or TP53R273H (right) mutations. (66) 
We reasoned that detection was limited by the low concentration of exosomal DNA, and 
decided that a functional abundance above 0.25% was a conservative and reliable threshold to 
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accurately define samples as ‘positive’ or ‘negative’ for the two mutations. Taking into 
consideration the respective false positive rates for each mutation, we defined a sample as 
‘positive’ for a given mutation if 1) the intensity of mutant allele was higher than 8800 A.U. 
(Fig. 23) and 2) the functional abundance, with the average false positive rate deducted (as 
described in experimental procedures), was greater than 0.25%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
	 77	
Figure 23. Representative 2D intensity scatter plot of wild-type and mutant amplicon for 
A) KRASG12D and B) TP53R273H. PDAC patients (P16, P50), an IPMN patient (P30), a CP patient 
(P66), and control spiked-in reactions (0.5% mutant). Threshold for mutant was set to 8800. 
Yellow = no DNA; blue = mutant; red = wild-type; green = mutant and wild-type. (66) 
Capture of KRASG12D and TP53R273H mutations in human serum by dPCR. 
 
Informed by the thresholds established by our control experiments, detection of 
KRASG12D and TP53R273H mutations could be performed using digital PCR (Fig. 23). For PDAC 
patients, KRASG12D and TP53R273H mutations were detected in 39.6% (19/48) and 4.2% (2/48) of 
the samples, respectively (Fig. 24A&B). The highest functional abundance observed was 
47.45% (patient P8) and 0.25% (patients P27 and P65) for KRASG12D and TP53R273H mutations, 
respectively (Fig. 24A). We found that 3 out of 7 IPMN patients harbored the KRASG12D 
mutation with the highest observed functional abundance at 2.17%, and one of these patients 
also co-harbored the TP53R273H mutation (0.52% functional abundance) (Fig. 24A&B). In CP 
patients, KRASG12D mutation was found in 5 out of 9 of the serum samples (highest functional 
abundance of 1.12%), but none were found to have the TP53R273H mutation (Fig. 24A&B). Five 
out of 12 (41.7%) patients diagnosed with other diseases (autoimmune pancreatitis, common 
bile duct cancer, pancreatic cystadenoma, pancreatic neuroendocrine tumor, duodenal adenoma, 
and uterine sarcoma harbored the KRASG12D mutation (highest functional abundance of 2.20%), 
and only 1 had the TP53R273H mutation (functional abundance of 0.33%). In healthy samples, the 
KRASG12D mutation was observed in 2.6% (3/114) of individuals, with highest functional 
abundance of 3.47% (Fig. 24A), and none had the TP53R273H mutation. 
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Figure 24. KRASG12D and TP53R273H detection in human serum samples. A) Functional 
abundance of KRASG12D (top) and TP53R273H (bottom) mutations for the indicated groups. B) 
Percent distribution of KRASG12D and TP53R273H mutations in the indicated groups with 
overlapping circles indicating individuals with both mutations. PDAC: n = 48, IPMN: n = 7, CP: 
n = 9, Others: n = 12, Healthy: n = 114. (66) 
 
This study indicates that even small amounts of serum, as low as 150 µl, can be used to 
isolate exosomes and purify DNA to identify cancer specific mutations in humans. We 
identified, in 48 serum samples from PDAC patients, KRASG12D mutation in 39.6% of the 
samples and TP53R273H mutation in 4.2% of them, leaving 27 samples without these 2 specific 
mutations. These results are relevant, as the prevalence of KRASG12D mutation identified using 
PDAC tumor tissue is approximately 40–50% (174). Therefore, this exosomal DNA study likely 
captures most of the anticipated KRASG12D mutations in PDAC patients. This also appears to be 
the case for TP53R273H mutation, with an estimated 7% of patients possibly presenting with a 
c.818G>A substitution reflecting the R273H mutation. Our study, using a large number of 
24 
A B 
	 79	
healthy subjects to detect cancer associated mutations in liquid biopsy, leads to a cautionary 
note that identification of driver mutations may not signify presence of disease. On the other 
hand, patients with CP (at higher risk of developing PDAC lesions) appear to present with a 
greater rate of KRAS mutation in our study. Indeed, while identification of highly prevalent 
mutations in circulating exosomal nucleic acids by itself may not offer a specific diagnosis, this 
approach, when combined with imaging modalities and other diagnostic procedure, may 
enhance personalized care of high-risk individuals. Circulating exosomal nucleic acid analyses 
may allow us to further develop precision medicine techniques for tailoring personalized care, 
with early detection and cancer prevention in mind. 
 
Novel and unique somatic variants in the DNA from urinary exosomes of BC patients 
Urine exoDNA is suitable for PCR-amplification & Sanger sequencing 
To determine whether urinary exoDNA can be used to identify hotspot mutations in BC, 
urinary exoDNA, matched tumor DNA, and PBMCs were PCR-amplified and subjected to 
Sanger sequencing. 15 primer sets targeting known BC hotspot regions in six genes (TERT, 
FGFR3, PIK3CA, TP53, HRAS, KDM6A) were utilized (Table 4) (50). Successful amplification 
of each target region was determined by gel electrophoresis and confirmed by Sanger 
sequencing. For each of the six queried targets, a positive result was observed with urinary 
exoDNA from at least one patient (Fig. 25A). Urine exoDNA from the patient 1 sample set 
showed the highest representation of queried genes, with positive PCR amplification for all 15 
targets. Sanger sequencing performed for a subset of targets in PBMC, tumor, and urine 
exoDNA, resulted in base calls with distinct peaks for all samples, indicating high quality 
sequencing suitable for detecting mutations. A representative comparison of base calls from the 
patient 2 sample set in a mutational hotspot region of TP53 is shown (Fig. 25B). 
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Figure 25. PCR & Sanger sequencing of BC hotspots in patient samples. A) Gel 
electrophoresis of PCR hotspot targets in urinary exoDNA samples. B) Representative Sanger 
sequencing alignment of TP53 hotspot PCR product in PBMC, tumor, and urine exoDNA from 
patient 2.  
 
WES of exoDNA can be negatively impacted by non-uniform whole-genome amplification 
Whole exome sequencing (WES) data generated by Illumina HiSeq 3000 yielded a high 
mean target coverage (³100X) for all but three samples using 76 bp paired-end reads. However, 
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the median coverage for most exoDNA samples was poor, indicating a subset of targets with a 
much higher coverage than the rest of the genome. This can be attributed to using whole-
genome amplification (WGA) prior to library preparation for exoDNA samples, which is 
necessary to generate a DNA concentration suitable for WES, based on current technology 
requirements. Similar low-template WGA procedures have been known to create amplification 
bias and poor coverage, especially in samples with varying quality (175-177). This diminished 
coverage in some of our samples was also reflected in the total number of variants identified per 
sample, as well as in concordance and contamination data (Table 6A-E). 
 
Variant analysis revealed superior mutation capture in urinary exoDNA samples 
Comparison of the mutational profiles in tumor samples revealed a range of 107-152 
total somatic driver gene variants in individual samples, with 5-12 variants shared between at 
least two patient samples (Table 7). Additionally, seven variants were shared among three of 
the patients, and one variant was common among four patients (P1/2/4 & 5, STK11/rs10415095, 
Table 8). KLK10 and IGF1R were the two most commonly mutated somatic driver genes across 
all tumor samples (Table 9).  
 
 P1 P2 P4 P5 P6 Total 
P1 90 6 11 9 5 124 
P2 6 109 12 10 7 144 
P4 11 12 71 11 6 117 
P5 9 10 11 110 5 152 
P6 5 7 6 5 81 107 
Table 7. Total shared & unique somatic variants in driver genes in tumor samples. The 
number of variants unique to each patient tumor sample are highlighted in blue. The total 
number of somatic driver variants in tumor samples from each patient are highlighted in yellow. 
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 Gene dbSNP ID CGI BC? 
RefSeq 
Func P1 P2 P4 P5 P6 
1 STK11/LKB1 rs10415095 No UTR3 U, T T T S, T - 
2 KLK10 rs11343599 No UTR3 U, T T - U, S, T - 
3 IGF2 rs58312807 Yes UTR3 - T T U, S, T - 
4 AKT1 rs1130214 No UTR5 U, T S, T - T - 
5 PSCA rs2976396 Yes UTR3 - U, T T - U, T 
6 PTK2 rs13258775 Yes UTR5 - T - T U, T 
7 PLEKHG2 rs251860 No UTR3 U T T T U 
8 ETV6 rs1051782 No UTR3 - T - T T 
9 RASSF2 rs2422978 No UTR3 - - T T T 
Table 8. Top common somatic variants in driver genes in tumor samples. A novel SNV in 
the 3’UTR of the STK11/LKB1 gene was the only somatic driver variant shared in four tumor 
samples. Variants were first ranked by prevalence across tumor samples, and then by prevalence 
in multiple samples from a single patient. CGI BC status indicates if this gene has been 
previously known to be associated with bladder cancer based on data from the Cancer Gene 
Index. U: Urine, T: Tumor, S: Serum. 
 
 Gene # Variants 
CGI 
BC? P1 P2 P4 P5 P6 
1 KLK10 20 No 4 6 3 7 0 
2 IGF1R 15 Yes 6 2 3 3 1 
3 SYNPO2 7 Yes 1 1 1 1 3 
4 CREB3L2 6 No 2 1 1 1 1 
5 PLEKHG2 6 No 1 1 1 2 1 
6 IGF2 8 Yes 0 1 2 4 1 
7 AKT1 8 No 2 1 3 2 0 
8 AKAP13 8 No 3 0 1 3 1 
9 ELAC2 7 No 2 2 2 1 0 
10 RASSF2 7 No 0 1 1 3 2 
Table 9. Most commonly mutated driver genes in tumor samples. Genes were ranked based 
on the total number of variants found in that gene across patient tumor samples. CGI BC status 
indicates if this gene has been previously known to be associated with bladder cancer based on 
data from the Cancer Gene Index. 
	 83	
Analysis of exoDNA samples revealed superior capture of BC tumor mutations in the 
urinary versus serum exosomes, as well as identification of de novo mutations that were not 
detectable in the matched tumor tissues. The genes with the most frequently identified variants 
unique to urine samples were ranked, including KRAS in three of five patients (Table 10).  
 
 
 
 
Table 10. Top driver variants unique to urine samples. Genes were ranked based on the total 
number of variants found in that gene across patient urine samples. Shaded cells indicate that 
variants in that gene were identified in multiple patient urinary exoDNA samples. 
 
When comparing somatic variants of cancer-associated genes (drivers) identified in 
tumor samples to those found in matched exoDNA, 22-74% of total variants were unique to 
tumor samples, 20-54% found exclusively in the urinary exoDNA, and 11-14% unique to serum 
samples (excluding those with poor median target coverage). Additionally, individual patient 
samples showed 7-21% overlap between urine and tumor, 5-6% between serum and tumor, and 
5-8% between urine and serum. Lastly, in the two patients with the highest quality WES data 
(sets P2 and P5), 6% of somatic driver variants were shared between tumor, urine, and serum 
(Fig. 26). Patient 2 shared variants across the three samples in ARHGAP35, ELAC2, ID4, 
KLK10, and NMT1. Patient 5 shared variants across the three samples in AKAP13, IGF2, 
KLK10, and SUFU.  
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Figure 26. Overlap in somatic variants identified in the urinary exoDNA, serum exoDNA 
and tumors of individual patients. A) Comparative analysis of somatic driver gene variants 
showed 22-74% were found in the tumor (T) DNA only, 7-54% were in the urinary (U) 
exoDNA samples only, and 3-17% were unique to serum (S) exoDNA samples. Up to 21% 
somatic driver variants were shared between the tumor and urinary exoDNA (T/U), 0-6% were 
shared between tumor and serum exoDNA (T/S), and 0-8% were common between the urine 
and serum samples (U/S). 0-6% were common between tumor, urine exoDNA, and serum 
exoDNA (T/U/S). B) Comparative analysis of all somatic variants showed a similar distribution 
with 26-70% of all variants unique to tumor samples, 11-50% unique to the urinary exoDNA, 
and 4-15% unique to serum exoDNA samples. Up to 20% were shared between tumor and urine 
samples, 0-5% between tumor and serum samples, 0-6% between urine and serum samples, and 
0-4% between tumor, urine, and serum in individual patients. 
 
 
 
A 
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BC patient panels have a high proportion of mutations in untranslated regions (UTRs) 
Variant analysis of the WES data from tumor tissues and exoDNA using matched PBMC 
DNA as the reference sequence revealed a number of somatic variants in 3’ and 5’ untranslated 
regions (UTRs) of all samples, which were considerably more prevalent compared to the 
variations in the exonic regions. Non-coding sequence variants in 3’ and 5’ UTRs have recently 
been associated with high-penetrance hereditary disorders. Significant polymorphisms in the 5’ 
regions (178-181)  and in the 3’UTRs were linked to glioma, colon, breast, and ovarian cancers 
(182-185). A recent study, which provides means of a unified analytic framework to prioritize 
such non-coding variants revealed over 130 potentially deleterious polymorphisms in breast and 
ovarian carcinoma (186). We found that six of the UTR variants localized in the miRNA 
binding domains of potential driver genes, suggesting that these mutations may interfere with 
miRNA binding to the gene transcripts and therefore prevent post-transcriptional regulation and 
promote cancer progression (Table 11). 
 
 
 
 
Table 11. Mutated miRNA binding sites in driver genes. Six variants were found to be located 
in predicted miRNA binding domains, which disrupts post-transcriptional regulation of these 
drivers and may contribute to the progression of bladder cancer in these patients. Note the two 
KRAS mutations, one of which was identified in two urine exoDNA samples but absent in their 
matched tumor samples, and the other which was only identified in two tumor samples. 
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# of nodes 89
# of edges 194
Ave. node 
degree 4.36
Average 
clustering coeff. 0.398
Expected # of 
edges 116
PPI enrichment
p-value
2.37
E-11
Network has significantly 
more interactions than 
expected
Gene network reconstruction through identification of driver gene mutations 
Network reconstruction of driver genes with mutations shared across at least four 
patients revealed significant interactions between cancer-associated driver genes, primarily 
centered around the AKT1 pathway (Fig. 27).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Common network for driver genes shared between at least four patients. 
Network reconstruction of mutated driver genes (Pathways in Cancer, KEGG) shows highly 
significant interaction of cancer-associated driver genes, with most abundant clustering around 
the AKT pathways. Major oncogenic nodes are shown in red. AKT pathway (black arrows), 
KRAS pathway (white arrows), Wnt pathway (closed triangles), and TGF-b pathway (open 
arrows). 
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In addition, the network analysis using matched urinary exoDNA and tumor samples from 
patient 2, for example, showed good overlap and a tight network centered around pathways with 
strong cancer relevance, which include oncogenes AKT1/2, BCL2, KRAS, MDM2, PDGFRB, 
AXIN1, IGF1R, tumor-suppressive LATS1 and BRCA1, and immunomodulatory IL4R (Fig. 28).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
A 
B 
28 
	 88	
Figure 28. Networks and driver genes in the urinary exoDNA and matched tumor DNA of 
patient 2. A) Urinary exoDNA. B) Matched tumor sample. Note tight networks clustering 
around KRAS and AKT pathways, with mutated tumor suppressor pathways (TSC1, BRCA1) and 
altered TP53 pathway (MDM2). Note a significantly higher representation of mutated genes in 
the urinary exoDNA for this sample set. 
 
 Thus, we have demonstrated that genomic DNA can be found in exosomes of BC patients, 
but not those not of healthy donors using the same sample volumes. This urinary exoDNA can 
be used to identify cancer-specific mutational profiles, which partially match the profiles of 
parental tumor and represent the pathways and signatures characteristic for bladder cancer. 
Furthermore, our research suggests that urinary exoDNA is superior to serum exoDNA for 
mutational analysis of bladder cancer. Finally, urinary exoDNA contains subsets of mutations 
that are absent in the matched tumor specimens, likely due to the limited representation of the 
highly heterogeneous bladder tumor tissue in a small biopsy. 
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Chapter 5 
Investigation of the origin and function of exoDNA 
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Assessing nuclei as sources of exosome-like particles  
Isolated nuclei produce exosome-like vesicles that contain genomic DNA 
Since exosomes contain genomic DNA, we investigated the possibility of vesicle 
generation directly from the cell nuclei. To observe the release of nuclear vesicles (NV), nuclei 
were isolated from Panc-1 and T3M4 cells using either a 0.5% Tween-20 or a 0.5% NP-40 lysis 
buffer. DNA and remaining endoplasmic reticulum (ER) were visualized by fluorescence 
microscopy using DAPI and ER Tracker Red, respectively, which showed that the NP-40 lysis 
buffer efficiently removed the ER from nuclei (Fig. 29A). This isolation method was then used 
for all subsequent experiments.  
 Nuclei were placed in tissue culture dishes in an isotonic buffer at physiological pH and 
incubated at 37°C (20% O2, 5% CO2 for 24, 48, and 72 hours to determine the kinetics of NV 
release. The number of NVs released into solution was determined by NanoSightTM. Similar to 
exosomes, NVs were released over 48 hours of incubation; however, unlike exosomes, which 
are continuously released for at least 72 hours, NV abundance dramatically declined after 48 
hours (Fig. 29B). The cause for this is unknown, but could be due to loss of vesicle integrity at 
some point between 48 and 72 hours. NanoSightTM measurements for both Panc-1 and T3M4 
NVs showed diameters similar to those of exosomes (Fig. 29C). DiO staining followed by 
sucrose gradient separation showed that Panc-1 NVs float at the same density as Panc-1 
exosomes (Fig. 29D). FACs analysis of Panc-1 and T3M4 NVs showed that unlike exosomes, 
NVs from both cell lines are negative for tetraspanin exosome markers (Fig. 29E). TEM of 
T3M4 EVs demonstrated relative structural integrity and bilayer membrane of the resultant 
particles. (Fig. 29F). TEM also confirmed that isolated nuclei were free of ER traces (Fig. 29F). 
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Figure 29. Cell nuclei shed exosome-like vesicles in ex vivo conditions. A) Nuclei were 
isolated using Tween-20 (left) or NP-40 (right) lysis buffers and stained with DNA (blue, DAPI) 
and endoplasmic reticulum (red, ER Tracker Red) fluorescent dyes. B) Isolated nuclei were 
incubated for the indicated time periods and NVs were isolated by ultracentrifugation and 
quantified by nanotracking analysis (NanosightTM). C) Representative nanotracking plots of 
vesicle preparations from the Panc-1 and T3M4 nuclei. D) Top-to-bottom sucrose density 
gradient was layered with DiO-labeled NVs from Panc-1 and HPNE cells, and control RPMI 
medium. Density and fluorescence intensity at 488 nm wavelength of NV-containing and 
adjacent fractions were determined to demonstrate the similarities between NVs and exosomes. 
E) Flow cytometry analysis of Panc-1 (top) and T3M4 (bottom) NVs for common tetraspanin 
exosome markers. F) Representative TEM of isolated T3M4 nuclei (left) and NVs (right). 
 
Characterization of the DNA content of Panc-1 and T3M4 NVs also showed that the DNA 
associated with NVs is protected from DNase I. The NV DNA concentration reached its peak at 
24 hours (Fig. 30A). Furthermore, fragment length profiling of intact and DNase I-treated NVs 
was similar to those found in matched exoDNA preparations (Fig. 30B).  
Due to the endosomal origin of exosomes, it is equally possible that exoDNA originates 
from the cytoplasm, the nucleus, or is absorbed from the extracellular space. To differentiate 
between these sources, cellular DNA in live T3M4 was labeled with Hoechst 33342. The cells 
were then incubated in media, to which SYTO 16-labeled genomic or exosomal DNA was 
added and the DNA uptake observed by fluorescence microscopy. Exosomes were then 
collected and the uptake of foreign DNA material was examined. SYTO 16 signal was not 
detectable in the recipient cells by fluorescence microscopy, however cells incubated with 
isolated cellular or exoDNA presented with high rates of formation of micronuclei or nuclear 
protrusions, respectively, suggesting that following DNA uptake it was either segregated into 
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micronuclei or retained in the cytoplasm causing nuclear rupture. Of note, exosome from the 
cells incubated with exogenous genomic DNA showed a higher Hoechst 33342 signal 
(incorporation of endogenous nuclear DNA). In addition, incubation with exogenous DNA 
resulted in a slight increase of the exosomal SYTO16 levels compared to control. These 
observations suggest that most of the exosomal DNA originates from the nuclei of parental 
cells, however exogenous DNA may be incorporated as well. Furthermore, the presence of 
exogenous DNA led to increased packaging of endogenous nuclear DNA into exosomes, as 
shown by increased Hoechst 33342 signal in isolated exosomes after cells were treated with 
exogenous DNA (Fig. 30C). 
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Figure 30. Characterization of NV DNA. A) NVs collected at different time points as in panel 
B were exposed to control buffer or DNase I solution. Following DNase I exposure, NVs were 
lysed and DNA isolated and quantified by Qubit. B) Fragment length of NV DNA was assessed 
by capillary electrophoresis (Bioanalyzer). C) Live T3M4 cells with Hoechst 33342-stained 
nuclei were incubated with serum-free medium alone, or 250ng SYTO-16 (488 nm emission 
peak)-stained T3M4 gDNA or exoDNA (5ng for microscopy samples). Fluorescence imaging 
was performed to assess exosome uptake and localization. Actin cytoskeleton was visualized by 
Phalloidin 647 staining. Collected exosomes from 5,000,000 cells incubated with 250ng DNA 
were DNase I treated and analyzed by fluorescence measurement at 350nm (Hoechst) and 
488nm wavelengths (SYTO16) to evaluate the origin of internal exoDNA. 
 
Exosomes deliver transcriptionally-active gene fragments to recipient cells 
To evaluate the potential of exosomes for in vivo DNA transfer, nude mice were injected 
once i.p. with PKH-labeled Panc-1 exosomes that were collected from conditioned serum-free 
media that was incubated with cells in two 225 cm2 flasks for 48 hours. Pancreas and liver 
tissues were collected 3 hours post injection, nuclei stained with DAPI, and examined for 
exosome uptake by fluorescence microscopy. To assess horizontal DNA transfer in these 
tissues, a human KRAS DNA fragment from exon 2 was PCR-amplified using human-specific 
primers. Fluorescence imaging detected PKH-labeled exosomes in the livers and, more 
abundantly, in the pancreata of recipient mice (Fig. 31A). PCR amplification of total DNA from 
these tissues suggested that the human-specific KRAS DNA sequences were transferred to the 
tissues of recipient mice (Fig. 31A). 
To assess exosome interaction with recipient cells, Panc-1 exosomes were PKH26-
labeled and added to the epithelial-like pancreas cells (HPNE), breast epithelial cells (HMLE), 
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or foreskin fibroblasts (BJ). Fluorescence microscopy demonstrated similar localization of 
exosomes in phalloidin-labeled cells, regardless of cell type (Fig. 31B). To assess DNA transfer, 
mouse pancreas fibroblasts (1493 cell line) were incubated with Panc-1 or T3M4 exosomes and 
the presence of exoDNA was assessed 3 hours after treatment or 24 hours later. PCR with 
human-specific primers showed the presence of exons 5-8 of human TP53 exosome-treated 
1493 cells at both time points, but not in untreated control (Fig. 31C). Furthermore, in 1493 
cells treated with Panc-1 exosomes, Sanger sequencing identified the KRAS G12D (G>A) 
mutation, which is specific to Panc-1 cells (Fig. 31D). RT-qPCR of cDNA generated from 1493 
cells exposed to Panc-1 or T3M4 exosomes using primers that specifically amplify human 
KRAS transcript revealed that expression of the human-specific transcript only occurred in cells 
that were exposed to Panc-1 or T3M4 exosomes, and not in untreated cells (Fig. 31E). These 
results suggest that exoDNA from Panc-1 or T3M4 exosomes included human KRAS sequence, 
which were transcribed by the recipient cell machinery. To test whether this transfer of genetic 
material was through exosomal cargo (intraluminal DNA) and not the uptake of free DNA, 1493 
cells were incubated with either purified Panc-1 or T3M4 exoDNA or exoDNA pre-packaged 
into cationic microvesicles (lipofectamine) prior to incubation. Human TP53 sequences were 
only detected when exoDNA was incubated with lipofectamine, suggesting that DNA uptake is 
dependent on the cationic lipid membranes of the carrier vesicles (Fig. 31F). 
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Figure 31. ExoDNA is taken up by cells in vitro and in vivo and can be utilized as a 
template for mRNA synthesis. A) Nude mice received i.p. injections of PKH-26 labeled Panc-
1 exosomes. Exosome localization in liver and pancreas was detected by fluorescence 
microscopy and exoDNA was traced by PCR amplification of a 166 bp fragment of exon 2 of 
human KRAS gene (right). B) Cultured human and mouse epithelial cells and human fibroblasts 
were incubated with PKH-26 labeled exosomes (2000 exosomes cell-1) for 3 hours and exosome 
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uptake examined by fluorescence microscopy. Cell nuclei were visualized with DAPI (blue) and 
actin cytoskeleton highlighted by Phalloidin 488 staining (green). C) 1493 cells were treated 
with Panc-1 or T3M4 exosomes and DNA was isolated 3 hours after incubation or after 24 
hours. PCR was performed to amplify human-specific TP53 sequence. DNA from untreated 
1493 cells was used as a negative control, and Panc-1 or T3M4 cellular DNA were used as 
positive controls. D) DNA isolated from 1493 cell DNA after incubation with Panc-1 exosomes 
at indicated time points was subjected to Sanger sequencing seeking human-specific KRAS 
mutations transferred by exosomes. E) Human-specific KRAS mRNA in 1493 cells after 
incubation with Panc-1/T3M4 exosomes was measured by qRT-PCR. Fold change was 
calculated by normalizing to the internal reference sequence (mouse ß-actin). F) Isolated Panc-1 
or T3M4 exoDNA were pre-incubated with control buffer or Lipofectamine 2000 and added to 
1493 cells. DNA isolated from treated 1493 cells was subjected to PCR with primers to amplify 
human-specific TP53 sequence. DNA from untreated 1493 cells was used as a negative control.  
 
Our study shows nuclear DNA can be packaged into exosomes, and this process may 
include the formation of nuclear vesicles. ExoDNA is nuclease-resistant due to the protective 
membrane and can be delivered on an organismal level, to distant tissues, where it can be 
utilized as a template for gene expression and therefore may impinge on the phenotype of 
recipient cells.  
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Discussion and Future Directions 
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Discussion 
Confirmation of the intraluminal localization of genome-spanning exoDNA 
This study confirms the presence of genomic DNA in exosomes using an array of 
experimental strategies. Differential sensitivity to DNase I added pre- and post-lysis showed that 
indeed, exoDNA is intraluminal and protected by the exosomal membrane. Mass cytometry 
(cyTOF) analysis revealed the heterogeneity of the Panc-1 and T3M4 exosome populations 
(those that contain both GAPDH and IdU/DNA, GAPDH, but no IdU/DNA and IdU/DNA-
containing exosomes negative for GAPDH). It is, however, not impossible that asymmetrical 
distribution of IdU between exosome populations may be due to the fact that IdU is incorporated 
in replicating DNA during S phase and the only exosomes that register in such assay as DNA 
(IdU) positive are the ones that were generated by cells in S phase. However, the heterogeneity 
of exosomal populations have been previously suggested by the work of others (187-190). For 
instance, exosomes released from the organoids formed by colon carcinoma cells could be 
separated into two distinct populations based on the expression of epithelial antigen A-33 vs. 
Ep-Cam (191). The use of beads instead of individual exosome analysis is also potentially 
confounding since multiple exosomes could bind to a single bead. However, the high sensitivity 
of cyTOF allows for detection of even weak positive signal, and the presence of beads positive 
for GAPDH alone implies that exosome populations are indeed heterogeneous. Further evidence 
of the intraluminal DNA localization in Panc-1 exosomes was provided by analysis of the DNA 
content in DiO-stained and DNase I-treated exosomes after separation on a sucrose gradient.  
 The results that were observed from cell line exosomes were also confirmed in BC 
patient serum and urine samples. Based on previously published work and the existing need for 
better biomarkers, BC was chosen as the ideal disease setting to study urinary exoDNA. Our 
study confirms the elevated exosome content in the urine of bladder cancer patients, which was 
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demonstrated previously by using an integrated double-ultrafiltration device conjugated to a 
nanochip (192). Additionally, we report for the first time that genomic DNA is contained within 
urine exosomes and there is high exoDNA content in DNase I-treated urinary exosomes from 
BC patients compared to healthy donors. Thus, our findings refute previously published work 
(193, 194), but may have broader implications if confirmed with additional research, since the 
presence of tumor DNA in urinary exosomes could be used in lieu of cystoscopy for accurate 
and sensitive detection of recurrent BC. In contrast, serum exosomes presented with detectable 
baseline levels of healthy exoDNA, which were not significantly altered in the patients with BC. 
Therefore, urine exosome and exoDNA concentration alone may prove to be a biomarker for 
BC when evaluated in larger patient cohorts. 
 
ExoDNA is a suitable template for dPCR and next generation sequencing 
 Copy number analysis generated by WGS experiments showed a prodigious degree of 
overlap between exoDNA and cellular genomic DNA in all sequenced cell lines. Importantly, 
this remained true for exosomes treated with DNase I, and is another demonstration of 
intraluminal localization of exoDNA. The similarity of CNA profiles generated for exoDNA 
and cellular DNA was remarkable regardless of the method of exosome isolation 
(ultracentrifugation or commercially-available PEG-based precipitation reagent) and showed 
that as a collection, exosomes contain DNA that spans the entire genome in multiple cell lines 
from different tissues. However, correlation was impacted by low mean coverage, leading to 
lower confidence in calling true deletions. This suggests that deeper sequencing could improve 
the correlation rate and also allow for high-confidence comparative analysis of specific variants. 
 After this confirmation was done from cell line exoDNA, we decided to expand on 
previous research from our laboratory, where KRASG12D and TP53R273H mutations were 
identified in PDAC patient serum exosomes (63). In this work, we screened a larger cohort of 
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banked healthy donor and patient serum exosomes for these mutations using the highly sensitive 
dPCR technique, which revealed similar clinical detection rates of these mutations in PDAC 
patients, suggesting that this may be a reliable non-invasive approach for monitoring tumor 
status based on mutant allele frequency. However, a small percentage of healthy donor serum 
exosome samples also contained the oncogenic KRASG12D mutation. Since monitoring and 
follow-up sample collections from these patients was not done, it’s not possible to determine if 
these mutations were real and/or led to the development of PDAC or other cancer. For a test like 
this to be implemented clinically, these unknowns will need to be addressed before it can be 
used in an adjuvant setting to supplement other diagnostic methods. 
Our results were also promising in the BC setting, suggesting that exosome or exoDNA 
concentrations alone may have utility as a biomarker. Since the amount of DNA in urinary 
exosomes of healthy donors is low, it is likely that exoDNA from the urine of BC patients is 
primarily derived from tumor cells. This could therefore result in a higher signal-to-noise ratio 
compared to that in cfDNA or in serum exoDNA. The poor representation of BC DNA in the 
serum exosomes suggests that bladder tumor cells may shed exosomes into the urine at a higher 
rate than into vasculature, possibly due to a higher proportion of tumor cells being directly 
exposed to the bladder lumen as opposed to blood vessels, and is supported by previous findings 
(49, 52). This leads to the notion that urine is a superior source for BC-related biomarkers. 
Therefore, our research suggests the collective sequencing of both tumor biopsy DNA and urine 
exoDNA reflects the genetic heterogeneity of the tumor more completely than a limited biopsy 
specimen alone. The unique subsets of mutations found specifically in urinary exoDNA argue in 
support of this concept. 
UTR variants are often excluded from WES bioinformatics pipelines, which are 
generally focused on coding regions, but the significance of UTR mutations for mRNA and non-
coding RNA regulation in cancer is increasingly appreciated (195-200). Indeed, despite the bias 
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towards the somatic driver variants, which were found predominantly in the UTRs and intronic 
regions, our computational analysis of mutational profiles in the exoDNA of BC patients using 
LynxKB software tools (169) implicated multiple cancer-associated pathways, including those 
specific for bladder cancer. Among them were pathways supporting cancer cells themselves as 
well as those more attributed to the tumor microenvironment (angiogenic factors, inflammatory 
chemokines and their cognate receptors).  
The most affected cancer-driving nodes across the majority of the patients found in the 
urinary exoDNA and the tumor tissue DNA included AKT1-3, BCR, FOXO3, IGF2, KRAS and 
MTOR/RPTOR, all of which affect cancer cell proliferation, survival and metabolism (201-209). 
Frequent mutations in the SMO/WNT/FZD module found in three out of six patients suggests 
epithelial to mesenchymal transition may have occurred in the invasive BC tumors (210), or 
potentially a switch to the activated state of tumor stroma (211, 212). The significant overlap 
between the main driver nodes involved in cancer progression and the TME lend further 
supports to the validity of using urinary exoDNA as a non-invasive biomarker for BC and 
potentially other cancer types. The angiogenesis-related genes with mutations found both in the 
urinary exoDNA and in matched tumor samples included VEGFB, PDGFRA, and PDGFRB. In 
addition, significant mutational burden in the IL4R and IL6R genes could potentially augment an 
inflammatory microenvironment.  Lastly, analysis of mutational profiles using the SomaMIR 
database identified mutations in the miRNA binding domains of multiple cancer-associated 
genes, including two in the 3’UTR of the KRAS gene. 
Thus, we have demonstrated that genomic DNA can be found in significant amounts in 
exosomes of BC patients but not those of healthy donors. This urinary exoDNA can be used to 
identify cancer-specific mutational profiles, which partially match the profiles of parental 
tumors and represents the pathways and signatures characteristic for bladder cancer. 
Furthermore, our research suggests that urinary exoDNA is superior to serum exoDNA for 
	 103	
mutational analysis of bladder cancer. Finally, urinary exoDNA contains subsets of mutations 
that are absent in the matched tumor specimens, likely due to the limited representation of the 
highly heterogeneous bladder tumor tissue in a small biopsy.  
 
exoDNA may originate from nucleus-derived vesicles and can be horizontally transferred 
 The origins of DNA in exosomes are still being debated. Research from others suggests 
that fragmented nuclear DNA is segregated into rupture-prone micronuclei, which consequently 
release genomic DNA fragments into cytoplasm (148). Direct rupture of the nuclear membrane 
due to physical pressure from surrounding environment during migration can also lead to 
cytoplasmic DNA localization (213-215). Another study demonstrated that packaging of 
cytoplasmic DNA fragments in exosomes is part of homeostatic response to bypass aberrant 
STING response (68). Taken together, these studies imply that genomic DNA is incorporated 
into exosomes via a cytoplasmic route that involves nuclear/micronuclear rupture. There is 
currently no evidence directly linking nuclear rupture with exoDNA content, however several 
studies demonstrate the possibility of the nuclear origin of EVs, including the presence of a 
nuclear protein high mobility group box protein (HMGB) 1 in the EVs derived from LPS-
stimulated mouse macrophages or in the blood of human volunteers (216, 217). Rappa et al. 
report on the association between late endosomes and invaginations in the nuclear envelope, 
which allows for the transport of exosomal materials to the nuclei, via nuclear pores (218).  It is 
possible that reverse transport (from the nuclei to exosomes) also takes place. Finally, time-
lapse imaging revealed a new type of membrane protrusions (“bead-on-a-string”) as a means of 
EV formation from nuclear membrane blebs (apoptotpodia) in apoptotic cells (219). Our studies 
using isolated nuclei show that in addition to DNA leakage to the cytoplasm or loss of nuclear 
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membrane integrity in apoptotic cells (220-222), fragmented nuclear DNA may also be 
packaged into exosome-like nanosized vesicles that bud directly from the nuclear membrane.   
Using isolated nuclei, we found that at least ex vivo, exosome-like vesicular 
nanostructures of nuclear origin are generated. These NVs showed remarkable similarity to 
exosomes with regards to their diameter, shape, enclosing membrane and, most importantly, 
intraluminal localization of genomic DNA. The observed differences in the kinetics of particle 
formation could be attributed to diminished particle stability in the chosen experimental 
conditions. The cessation of NV production could be caused by energy requirements or caused 
by other limiting factors that are exhausted in isolated nuclei after 48 hours. Further experiments 
will determine whether and how NVs and their DNA content are incorporated into exosome 
biogenesis pathways. Such mechanisms could be NV fusion with early endosomes prior to or 
during formation of intraluminal vesicles (ILVs) and multivesicular bodies (MVBs), or through 
release of NV DNA into the cytoplasm and successive uptake by endosomes/ILVs/MVBs. 
The analysis of differential staining of nuclear DNA in parent cells and of exogenous 
DNA in their microenvironment clearly demonstrate that most of the DNA found in exosomes 
originates from the nuclei of the donor cells and only a small fraction by endocytic uptake of 
free DNA. Taken together with FACs and cyTOF analysis, which implies heterogeneity of 
markers and DNA loading in exosomes, these data suggest that DNA-containing fractions of an 
exosome population could be derived from the NVs. This is the first indication of such a 
mechanism of exosome formation and further studies are needed to fully elucidate the 
mechanism(s) involved in exoDNA sorting and packaging. To date, a similar mechanism has 
been described exclusively for apoptotic bodies (223). It is currently accepted that exoDNA 
represents damaged DNA expunged from cells to prevent activation of repair mechanisms that 
induce cell cycle arrest and potentially activate survival mechanisms such as autophagy (115). 
Indeed, upon exposure to genotoxic agents such as topotecan or doxorubicin, DNA accumulates 
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in the cytosol and subsequently in exosomes in a non-specific manner, since no enrichment for 
specific DNA loci has been observed. Attenuated exosome secretion leads to DDR activation 
via the STING pathway, which can be limited by overexpression of cytoplasmic DNase2a (69). 
Our experiments show horizontal transfer of exoDNA in vivo and in cell culture. 
Interestingly, our imaging analysis frequently showed exosomes overlying cell nuclei, 
suggesting a possibility of direct exosome fusion to nuclei. On the other hand, our results 
demonstrate the requirement for a positively charged lipid membrane, underscoring the critical 
role of exosomes in horizontal DNA transfer on an organismal level.  Horizontal DNA transfer 
facilitated by exosomes has also been shown by others (224-226). For example, exosomes 
derived from c-HRAS-transformed rat intestinal epithelial cells (RAS-3) contained exoDNA 
encompassing HRAS sequence, which was transferred into immortalized rat fibroblasts and 
retained for up to 30 days (227). It is nevertheless unclear whether the resultant increase in 
fibroblast proliferation was a direct consequence of gene transfer or induced indirectly by other 
factors transferred by HRAS containing exosomes. Further analysis could clarify the precise 
route of internalization, localization, and functionality of exoDNA in recipient cells. 
Interestingly, non-nuclear transcription of cytoplasmic DNA by a membrane-associated RNA 
polymerase II has been reported, indicating that delivery of exoDNA to the nucleus may not be 
critical for use as a transcription template (228). Our initial analysis shows that exoDNA retains 
the ability to be utilized by host transcriptional machinery. Exosomes from the human cell lines 
Panc-1 and T3M4 were incubated with murine 1493 cells. RT-PCR analysis detected increased 
human-specific KRAS transcript 24 hours after treatment, suggesting de novo transcription of 
DNA fragments carried by exosomes and the possibility of altering the phenotype of recipient 
cells. Similar results have been published regarding BCR/ABL DNA sequences in exosomes 
from CML, which are transcribed in HEK293 cells and neutrophils (141, 229). Other studies 
suggest that exoDNA can activate anti-cancer immune response or promote a suitable 
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environment for metastatic outgrowth when a malignancy is present. In both cases, the 
activation of cytosolic DNA sensing pathway cGAS–STING (cyclic GMP-AMP synthase–
stimulator of interferon genes) is implicated (69, 115, 140, 141, 230, 231). 
 
Conclusions 
 In conclusion, this collective work advances the fields understanding of exosomes and 
their DNA content by demonstrating that exosomes from multiple cell lines and circulating 
bodily fluids in two different disease settings containing DNase I-protected genomic DNA. 
Most importantly, this is the first study demonstrating the presence of genomic DNA in urine 
exosomes, which are more abundant in the urine of patients with bladder cancer and span the 
entire genome. We have demonstrated the utility of this exoDNA for the non-invasive 
theranostic assessment and monitoring of both pancreatic and bladder cancer using next-
generation amplification and sequencing methods. Therefore, in addition to allowing serial 
assessment of tumor genetics, exoDNA may also reveal additional driver mutations that could 
be crucial to an accurate prognosis and more appropriate clinical treatment strategy.  
 Lastly, we provide preliminary results that suggest exoDNA is derived from the nucleus 
of an exosome-producing cell, which may involve packaging of genomic DNA into nuclear 
membrane-derived vesicles that are similar to exosomes in size and protect DNA from DNase I 
treatment. It remains to be determined if these vesicles are released from cells as a distinct 
population of extracellular vesicles or fuse with multivesicular bodies before exosome release. 
Regardless, it is evident that exoDNA can be horizontally transferred to other cells and used a 
transcription template, but the functional importance of this remains poorly understood for now. 
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Future directions 
Primary future directions in regards to exoDNA content will revolve around determining 
concentration and sensitivity threshold requirements for downstream assays, with the potential 
for the development of clinical tests. In addition, more research will be needed to directly 
compare the isolation difficulty and efficacy of exoDNA versus circulating tumor cells or 
circulating-free DNA as biomarkers for cancer and other diseases. Lastly, combinations of 
exosomal biomarkers and/or other clinical parameters will need to be evaluated to determine if 
superior specificity and sensitivity can be established to replace current practices. Much remains 
to be done in this space, but it is clear that exoDNA offers promise and unique advantages over 
other investigated biomarkers. 
In regards to performing next-generation sequencing with exoDNA, although 
encouraging, novel approaches will be needed to refine and optimize the parameters of analysis, 
and incorporate larger cohorts of patients with samples from serial time points. Most notably, 
sequencing results impacted by low-template WGA should be improved either by using 
alternative WGA methodologies that amplify the input more uniformly, or by defining 
minimum sample/exoDNA requirements needed to eliminate the WGA entirely. Now, 
additional research and longitudinal prospective trials with larger sample sets are needed to meet 
the rigorous validation requirements for reliable biomarker development. 
 Lastly, much work remains to be done to understand the origin and function of exoDNA 
in vivo. Specifically, the presence of nuclear vesicles in living cells could be visualized in living 
cells by using the lentiviral vectors NLS-GFP or NLS-RFP (nuclear localization sequence) in 
combination with DNA & nuclear membrane tags/stains. Additionally, the functional role of 
exoDNA could be further explored by using sophisticated methods involving loading exosomes 
with reporter plasmids of delivering Cre+ exosomes to genetically engineered mice lacking Cre 
and determine if and in which tissues recombination takes place. 
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